Amphastar Pharmaceuticals (AMPH) 10-Q 13 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 10, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Amphastar Pharmaceuticals, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	44,648,798
Amendment Flag	'false	'
Entity Central Index Key	'0001297184	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$72,881	$53,587
Restricted cash and restricted short-term investments	1,495	1,325
Accounts receivable, net	26,604	24,585
Inventories, net	88,052	69,916
Income tax refund and deposits	5,139	2,429
Prepaid expenses and other assets	4,913	5,033
Deferred tax assets	16,096	16,096
Total current assets	215,180	172,971
Property, plant, and equipment, net	134,112	116,619
Goodwill and intangible assets, net	43,221	40,163
Other assets	2,502	2,877
Deferred tax assets	6,118	6,118
Total assets	401,133	338,748
Current Liabilities:	'	'
Accounts payable	10,013	20,380
Accrued liabilities	10,446	7,628
Income taxes payable	2,791	2,847
Accrued payroll and related benefits	11,863	9,161
Current portion of product return accrual	2,498	2,639
Current portion of deferred revenue	14,596	643
Current portion of long-term debt and capital leases	10,078	22,104
Deferred tax liability	797	'
Total current liabilities	63,082	65,402
Long-term product return accrual	791	1,953
Long-term deferred revenue	2,143	2,625
Long-term debt and capital leases, net of current portion	41,271	10,069
Long-term deferred tax liabilities	10,726	7,154
Total liabilities	118,013	87,203
Preferred stock: par value $.0001; authorized shares—20,000,000; none issued	0	0
Common stock; par value $.0001; authorized shares—300,000,000; issued and outstanding shares—44,645,437 and 38,765,940 at September 30, 2014 and December 31, 2013, respectively	4	4
Additional paid-in capital	219,288	177,732
Retained earnings	65,631	73,809
Accumulated other comprehensive loss	-1,803	'
Total stockholders’ equity	283,120	251,545
Total liabilities and stockholders’ equity	$401,133	$338,748

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Common stock; par value (in Dollars per share)	$0.00	$0.00
Common stock; authorized shares	300,000,000	300,000,000
Common stock; shares issued	44,645,437	38,765,940
Common stock; outstanding shares	44,645,437	38,765,940

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenues	$59,711	$59,318	$154,584	$174,805
Cost of revenue	47,920	39,038	115,288	107,478
Gross profit	11,791	20,280	39,296	67,327
Operating expenses:	'	'	'	'
Selling, distribution, and marketing	1,454	1,462	4,066	4,059
General and administrative	9,556	9,545	25,040	22,966
Research and development	8,585	9,041	20,788	25,736
Impairment of long-lived assets	13	6	361	6
Total operating expenses	19,608	20,054	50,255	52,767
Income (loss) from operations	-7,817	226	-10,959	14,560
Non-operating income (expense):	'	'	'	'
Interest income	94	49	154	145
Interest expense, net	-504	-195	-1,159	-737
Other income (expense), net	243	255	-367	477
Total non-operating income (expense), net	-167	109	-1,372	-115
Income (loss) before income taxes	-7,984	335	-12,331	14,445
Income tax expense (benefit)	-2,605	494	-4,153	4,412
Net income (loss)	($5,379)	($159)	($8,178)	$10,033
Net income (loss) per common share:	'	'	'	'
Basic (in Dollars per share)	($0.12)	$0	($0.20)	$0.26
Diluted (in Dollars per share)	($0.12)	$0	($0.20)	$0.26
Weighted-average shares used to compute net income (loss) per common share:	'	'	'	'
Basic (in Shares)	44,644	38,709	41,060	38,708
Diluted (in Shares)	44,644	38,709	41,060	38,848

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net income (loss)	($5,379)	($159)	($8,178)	$10,033
Accumulated other comprehensive loss	'	'	'	'
Foreign currency translation adjustment	-1,535	'	-1,803	'
Accumulated other comprehensive loss	-1,535	'	-1,803	'
Total comprehensive income (loss)	($6,914)	($159)	($9,981)	$10,033

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash Flows From Operating Activities:	'	'
Net income (loss)	($8,178)	$10,033
Reconciliation to net cash provided by (used in) operating activities:	'	'
Impairment of long-lived assets	361	6
Loss on disposal of property, plant, and equipment	44	116
Depreciation and amortization of property, plant, and equipment	9,235	8,187
Amortization of product rights, trademarks, and patents	1,437	1,430
Amortization of imputed interest and debt discount	66	'
Employee share-based compensation expense	5,952	4,569
Non-employee share-based compensation expense	728	715
Reserve for income tax liabilities	'	89
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-2,019	5,430
Inventories, net	1,609	-8,694
Income tax refund and deposits	2,690	-92
Prepaid expenses and other assets	-1,318	-468
Income taxes payable	-5,456	-133
Accounts payable and accrued liabilities	3,578	1,342
Net cash provided by operating activities	8,729	22,530
Cash Flows From Investing Activities:	'	'
Acquisition of business	-18,352	'
Purchases of property, plant, and equipment	-11,118	-13,896
Capitalized labor, overhead, and interest on self-constructed assets	-555	-507
Purchase of trademarks and other intangible assets	'	-43
Sales of short-term investments, net	'	513
Decrease (increase) in restricted cash	-170	50
Deposits and other assets, net	350	-1,246
Net cash used in investing activities	-29,845	-15,129
Cash Flows From Financing Activities:	'	'
Net proceeds from issuance of common stock	38,018	'
Payments on repurchase of common stock	-485	-15
Net proceeds from exercise of common stock options	701	51
Proceeds from borrowing under lines of credit	25,000	51,000
Repayments under lines of credit	-40,000	-55,000
Proceeds from issuance of long-term debt	26,505	'
Principal payments on long-term debt	-7,149	-1,451
Net cash provided by (used in) financing activities	40,670	-5,670
Effect of exchange rate changes on cash	-260	'
Net increase in cash and cash equivalents	19,294	1,731
Cash and cash equivalents at beginning of period	53,587	50,213
Cash and cash equivalents at end of period	72,881	51,944
Noncash Investing and Financing Activities:	'	'
Equipment acquired under capital leases	78	712
Supplemental Disclosures of Cash Flow Information:	'	'
Interest paid	978	845
Income taxes paid	86	4,017
Costs Related to Public Offering [Member]	'	'
Cash Flows From Financing Activities:	'	'
Costs related to public offering	-1,920	'
Deferred Offering Cost [Member]	'	'
Cash Flows From Financing Activities:	'	'
Costs related to public offering	'	($255)

Note_1_General

Note 1 - General	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1.  General
	Amphastar Pharmaceuticals, Inc., a California corporation, was incorporated on February 29, 1996 and merged with and into Amphastar Pharmaceuticals, Inc., a Delaware corporation, in July 2004 (hereinafter referred to as “the Company”). The Company is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s inhalation products will be primarily distributed through drug retailers once they are brought to market.
	The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2013 and the notes thereto as filed with the Securities and Exchange Commission in the Company’s final prospectus for its initial public offering, or IPO, filed with the SEC pursuant to Rule 424(b) on June 25, 2014. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2.  Summary of Significant Accounting Policies
	Basis of Presentation
	All significant intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. The unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X. Some information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted pursuant to those rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.
	The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: International Medication Systems, Limited, or IMS; Amphastar Laboratories, Inc.; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; and Amphastar France Pharmaceuticals, S.A.S., or AFP.
	Amounts reclassified
	Certain amounts in the prior years’ financial statements have been reclassified to conform to the current year presentation. These reclassifications relate to the Company’s accounting for accrued chargebacks, which was originally included on the Company’s consolidated balance sheets as a liability and is now reflected as a reduction to accounts receivable. These reclassifications have no impact on net income or cash flows.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, liabilities for product returns and chargebacks, reserves for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, fair market values of the Company’s common stock, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.
	Foreign Currency
	The functional currency of the Company and its domestic and Chinese subsidiaries is the U.S. dollar, or USD.  The Company’s Chinese subsidiary, ANP, maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in the Company’s statement of operations.  The Company’s French subsidiary, AFP, maintains its books of record in Euros, which is the local currency in France and has been determined to be its functional currency. These books are translated to USD at the average exchange rates during the period.  Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date.  Equity is translated at the prevailing rate of exchange at the date of the equity transactions.  Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss).  Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure.
	Comprehensive Income (Loss)
	For the three and nine months ended September 30, 2014, the Company includes its foreign currency translation adjustment as part of its comprehensive loss as a result of establishing the Company’s subsidiary, AFP, in France.  For the three and nine months ended September 30, 2013, net income (loss) equaled total comprehensive income (loss).
	Financial Instruments
	The carrying amounts of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt and their carrying value approximates fair value. Their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 13).
	Deferred Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share-based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share-based awards.
	Business Combinations
	Business combinations are accounted for in accordance with Accounting Standards Codification, or ASC 805, Business Combinations, using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Under the acquisition method of accounting, the Company will identify the acquirer and the closing date and apply applicable recognition principles and conditions.
	Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred.
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or FASB, issued an Accounting Standard Update to the accounting guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued an accounting standards update that raises the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operation. It also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance will be effective for fiscal years beginning after December 15, 2014, which will be the Company's fiscal year 2015, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2016, which will be the Company's fiscal year 2017. The Company has not yet evaluated the potential impact of adopting the guidance on the Company's consolidated financial statements.
	In June 2014, the FASB issued an accounting standards update that requires a performance target that affects vesting of a share-based payment award and that could be achieved after the requisite service period to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized over the required service period, if it is probable that the performance target will be achieved. This guidance will be effective for fiscal years beginning after December 15, 2015, which will be the Company's fiscal year 2016, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods.  This guidance will become effective for the Company’s annual filing for the period ending December 31, 2016 and interim periods thereafter, and allows for early adoption.  The Company does not expect the adoption of the guidance will have a material impact on the Company’s consolidated financial statements.

Note_3_Business_Acquisition

Note 3 - Business Acquisition	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	3.  Business Acquisition
	Acquisition of Merck’s API Manufacturing Business
	On April 30, 2014, the Company completed the Merck API Transaction, which manufactures porcine insulin API and recombinant human insulin API. The purchase price of the transaction on April 30, 2014 totaled €24.8 million, or $34.4 million, subject to certain customary post-closing adjustments and currency exchange fluctuations. The terms of the purchase include multiple payments over four years as follows (see Note 13):
		Euros			U.S.
					Dollars
		(in thousands)
	At Closing, April 2014	€	13,252		$	18,352
	Dec-14		4,899			6,214
	Dec-15		3,186			4,041
	Dec-16		3,186			4,041
	Dec-17		500			634
		€	25,023		$	33,282
	In order to facilitate the acquisition, the Company established a subsidiary in France, AFP. The Company will continue the current site manufacturing activities, which consist of the manufacturing of porcine insulin API and recombinant human insulin API. As part of the transaction, the Company has entered into various additional agreements, including various supply agreements, as well as the assignment and licensing of patents under which Merck was operating at this facility. In addition, certain existing customer agreements have been assigned to AFP.
	Prior to the Merck API Transaction, Merck notified the Company of several items it had identified as part of its own internal auditing that relate to potential minor environmental issues.  The Company understands from Merck that it identified these items because the items were not in alignment with Merck’s own internal policies and procedures, and not because any of the items are in violation of any French environmental law or regulation.  Under a letter of understanding, or LOU, dated April 30, 2014, Merck has agreed to pay for the remediation costs up to certain dollar limits, and to date, all estimates suggest the cost of conducting the remediation will be less than those dollar limits.  The LOU also includes an indemnification provision that would require the Company to indemnify Merck for liability that might arise from performance of the remediation work itself but not for other types of liability.
	The transaction will be accounted for as a business combination in accordance to ASC 805. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:
		Fair Value
		Euros			U.S.
					Dollars
		(in thousands)
	Inventory	€	15,565		$	21,554
	Real property		4,800			6,647
	Machinery & equipment		6,800			9,417
	Intangibles		80			111
	Goodwill		3,155			4,369
	Total assets acquired	€	30,400		$	42,098
	Accrued liabilities	€	2,425		$	3,358
	Deferred tax liabilities		3,155			4,369
	Total liabilities assumed		5,580			7,727
	Total fair value of consideration transferred	€	24,820		$	34,371
	The Company’s accounting for this acquisition is preliminary.  The fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations and valuations, and the Company’s estimates and assumptions are subject to change as the Company obtains additional information for its estimates during the measurement period (up to one year from the acquisition date) including the completion of our analysis to determine the acquisition date fair values of certain tax-related items and residual impact on purchase accounting.  During the nine months ended September 30, 2014, the Company received updated information regarding its deferred tax liability and related goodwill recorded as of the acquisition date.  While finalizing acquisition accounting, the Company recorded a measurement period adjustment which impacted goodwill and deferred tax liability by $4.4 million and $4.4 million, respectively during the nine months ended September 30, 2014.  The operations of the acquired business have been included in the Company’s condensed consolidated financial statements commencing on the acquisition date. The results of operations for this acquisition have not been separately presented because this acquisition is not material to the Company’s condensed consolidated results of operations.
	The following unaudited pro forma financial information for the nine months ended September 30, 2014 and 2013 gives effect to the transaction as if it had occurred on January 1, 2013.  Such unaudited pro forma information is based on historical financial information prior to the transaction as well as actual results subsequent to the acquisition with respect to the transaction and does not reflect estimated operational and administrative cost savings, or synergies for periods prior to the transaction, that management of the combined company estimates may be achieved as a result of the transaction.  The unaudited pro forma information primarily reflects the additional depreciation related to the fair value adjustment to property, plant and equipment acquired, valuation step up related to the fair value of inventory and additional interest expense associated with the financing obtained by the Company in connection with the acquisition.
		Nine Months Ended
		September 30,
		2014			2013
		(in thousands,
		except per share data)
	Net revenues	$	156,868		$	185,293
	Net income (loss)		(9,407	)		10,827
	Diluted net income (loss) per share	$	(0.23	)	$	0.28
	Acquisition Loan with Cathay Bank
	On April 22, 2014, in conjunction with the Merck API Transaction, the Company entered into a secured term loan with Cathay Bank as lender. The principal amount of the loan is $21.9 million and bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 4.00%. Beginning on June 1, 2014 and through the maturity date, April 22, 2019, the Company must make monthly payments of principal and interest based on the then outstanding amount of the loan amortized over a 120 month period. On April 22, 2019, all amounts outstanding under the loan become due and payable, which would be approximately $12.0 million based upon an interest rate of 4.00%. The loan is secured by 65% of the issued and outstanding shares of stock in AFP and certain assets of the Company, including accounts receivable, inventory, certain investment property, goods, deposit accounts, and general intangibles but not including the Company’s equipment and real property.
	The loan includes customary restrictions on, among other things, the Company’s ability to incur additional indebtedness, pay dividends in cash or make other distributions in cash, make certain investments, create liens, sell assets, and make loans. The loan also includes customary events of defaults, the occurrence and continuation of any of which provide Cathay Bank the right to exercise remedies against the Company and the collateral securing the loan. These events of default include, among other things, the Company’s failure to pay any amounts due under the loan, the Company’s insolvency, the occurrence of any default under certain other indebtedness or material agreements, and a final judgment against the Company that is not discharged in 30 days.

Note_4_Revenue_Recognition

Note 4 - Revenue Recognition	9 Months Ended
	Sep. 30, 2014
Revenue Recognition Disclosure [Abstract]	'
Revenue Recognition Disclosure [Text Block]	'
	4.  Revenue Recognition
	Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements. The Company also records profit-sharing revenue stemming from a distribution agreement with Actavis, Inc., or Actavis (see Note 16). Profit-sharing revenue is recognized at the time Actavis sells the products to its customers. Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers, after the customer has accepted test samples of the products to be shipped.
	The Company does not recognize product revenue unless the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) transfer of title has occurred, (iii) the price to the customer is fixed or determinable, and (iv) collection is reasonably assured. Furthermore, the Company does not recognize revenue until all customer acceptance requirements have been met. The Company estimates and records reductions to revenue for discounts, product returns, and pricing adjustments, such as wholesaler chargebacks, in the same period that the related revenue is recorded.
	The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple deliverables.
	Provision for Wholesaler Chargebacks
	The provision for chargebacks is a significant estimate used in the recognition of revenue. As part of its sales terms with wholesale customers, the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products at the time wholesalers resell them under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations. The Company estimates chargebacks at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback rates, and current contract pricing.
	The provision for chargebacks is reflected in net revenues and a reduction to accounts receivables.  The following table is an analysis of the chargeback provision:
		Nine Months Ended				Year Ended
		September 30,				December 31,
		2014				2013
		(in thousands)
	Beginning balance		$	18,104			$	11,898
	Provision related to sales made in the current period			118,643				213,075
	Credits issued to third parties			(124,449	)			(206,869	)
	Ending balance		$	12,298			$	18,104
	Changes in chargeback provision from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by the wholesalers’, and on the wholesaler customer mix. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and makes adjustments when it believes that the actual chargebacks may differ from the estimates. The settlement of chargebacks generally occurs within 30 days after the sale to wholesalers.
	Accrual for Product Returns
	The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, products sold to Actavis are non-returnable.  The Company’s product returns primarily consist of the returns of expired products from sales made in prior periods.  Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for estimated returns. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and the introduction of new competition.  Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate.
	The provision for product returns is reflected in net revenues.  The following table is an analysis of product return liability:
		Nine Months Ended				Year Ended
		September 30,				December 31,
		2014				2013
		(in thousands)
	Beginning balance		$	4,592			$	2,673
	Provision for product returns			(261	)			2,711
	Credits issued to third parties			(1,042	)			(792	)
	Ending balance		$	3,289			$	4,592
	For the nine months ended September 30, 2014 and for the year ended December 31, 2013, the Company’s aggregate product return rate was 1.2% and 1.4% of qualified sales, respectively. The reduced product return rate resulted from a $1.3 million decrease in the 2014 provisions for product returns related to sales in prior periods.
	If the product return provision percentage were to increase by 0.1% of qualified sales, then an additional provision of $1.0 million and $0.9 million would result for the nine months ended September 30, 2014 and the year ended December 31, 2013, respectively.

Note_5_Income_Loss_Per_Share

Note 5 - Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	5.  Income (Loss) per Share
	Basic income (loss) per share is calculated based upon the weighted-average number of common shares outstanding during the period and contingently issuable shares such as fully vested deferred stock units, or DSUs, as of the date all necessary conditions for issuance have been met. Diluted income per share gives effect to all potential dilutive common shares outstanding during the period, such as stock options and nonvested DSUs.
	As the Company reported a net loss for the three and nine months ended September 30, 2014, the diluted net loss per share, as reported, is equal to the basic net loss per share since the effect of the assumed exercise of stock options and conversion of nonvested DSUs is anti-dilutive. Total stock options and nonvested DSUs excluded from the three and nine months ended September 30, 2014, net loss per share were 11,511,431 and 529,774, respectively.  Additionally, as the Company reported a net loss for the three months ended September 30, 2013, total stock options and nonvested DSUs excluded from the three months ended September 30, 2013 were 10,305,452 and 131,184, respectively.
	For the nine months ended September 30, 2013, options to purchase 8,391,236 shares of common stock with a weighted-average exercise price of $16.54 per share, respectively, were excluded in the computation of diluted net income per share because the effect from the assumed exercise of these options would be anti-dilutive.
	The following table provides the calculation of basic and diluted net income (loss) per common share for each of the periods presented:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
		(in thousands, except per share data)
	Basic and dilutive numerator:
	Net income (loss)	$	(5,379	)	$	(159	)	$	(8,178	)	$	10,033
	Denominator:
	Common shares outstanding		44,642			38,707			41,058			38,699
	Contingently issuable shares - vested DSUs		2			2			2			9
	Weighted-average common shares outstanding—basic		44,644			38,709			41,060			38,708
	Net effect of dilutive securities:
	Stock options		—			—			—			63
	Contingently issuable shares – nonvested DSUs		—			—			—			77
	Weighted-average common shares outstanding—diluted		44,644			38,709			41,060			38,848
	Net income (loss) per common share—basic	$	(0.12	)	$	0		$	(0.20	)	$	0.26
	Net income (loss) per common share—diluted	$	(0.12	)	$	0		$	(0.20	)	$	0.26

Note_6_Segment_Reporting

Note 6 - Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	6.  Segment Reporting
	The Company’s business is the development, manufacture, and marketing of pharmaceutical products. On April 30, 2014, the Company established AFP and as a result, during the quarter ended September 30, 2014, the Company changed the structure of its reportable segments, establishing two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC Topic 280, Segment Reporting.  The Company’s performance will be assessed and resources will be allocated by the CODM based on the following two reportable segments:
	-	Finished pharmaceutical products
	-	Active pharmaceutical ingredients, or API
	The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn®, naloxone, lidocaine jelly, as well as, various other critical and non-critical care drugs.  The API segment manufactures and distributes recombinant human insulin and porcine insulin.
	Selected financial information by reporting segment is presented below:
			Three Months Ended							Nine Months Ended
			September 30,							September 30,
			2014				2013			2014				2013
			(in thousands)
	Net revenues:
	Finished pharmaceutical products		$	53,729			$	59,318		$	148,500			$	174,805
	API			5,982				—			6,084				—
	Total net revenues			59,711				59,318			154,584				174,805
	Gross Profit:
	Finished pharmaceutical products			12,122				20,280			39,592				67,327
	API			(331	)			—			(296	)			—
	Total gross profit			11,791				20,280			39,296				67,327
	Operating expenses			19,608				20,054			50,255				52,767
	Income (loss) from operations			(7,817	)			226			(10,959	)			14,560
	Non-operating income (expenses)			(167	)			109			(1,372	)			(115	)
	Income (loss) before income taxes		$	(7,984	)		$	335		$	(12,331	)		$	14,445
	The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis.  The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.
	Net revenues and carrying values of long-lived assets of enterprises by geographic regions are as follows:
		Net Revenue							Net Revenue								Long-Lived Assets
		Three Months Ended							Nine Months Ended								September 30,			December 31,
		September 30,							September 30,
		2014				2013			2014				2013				2014			2013
		(in thousands)
	U.S.		$	53,729			$	59,318		$	148,500			$	174,805			$	98,744		$	99,398
	China			—				—			—				—				21,011			17,221
	France			5,982				—			6,084				—				14,357			—
	Total		$	59,711			$	59,318		$	154,584			$	174,805			$	134,112		$	116,619

Note_7_Customer_and_Supplier_C

Note 7 - Customer and Supplier Concentration	9 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	7.  Customer and Supplier Concentration
	Customer Concentrations
	Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc. or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Actavis, Inc. has exclusive marketing rights of the Company’s enoxaparin product to the U.S. retail pharmacy market. The Company considers these four customers to be its major customers, as each individually, and they collectively, represented a significant percentage of the Company’s net revenue for the three and nine months ended September 30, 2014 and 2013 and accounts receivable as of September 30, 2014 and December 31, 2013.  The following table provides accounts receivable and net revenues information for these major customers:
		% of Total Accounts						% of Net						% of Net
		Receivable						Revenue						Revenue
		September 30,			December 31,			Three Months Ended						Nine Months Ended
								September 30,						September 30,
		2014			2013			2014			2013			2014			2013
	Actavis, Inc.		31	%		44	%		35	%		32	%		33	%		34	%
	AmerisourceBergen		10	%		11	%		14	%		15	%		15	%		15	%
	Cardinal Health		10	%		7	%		13	%		13	%		14	%		14	%
	McKesson		16	%		13	%		19	%		29	%		23	%		26	%
	Supplier Concentrations
	The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent U.S. Food and Drug Administration, or FDA, requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

Note_8_Fair_Value_Measurements

Note 8 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	8.  Fair Value Measurements
	The accounting standards of the Financial Accounting Standards Board, or FASB, define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:
		·	Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;
		·	Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and
		·	Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.
	The Company measures fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	The Company classifies its cash equivalents and short-term investments as Level 1 assets, as they are valued on a recurring basis using quoted market prices with no valuation adjustments applied. The Company does not hold any Level 2 or Level 3 instruments that are measured for fair value on a recurring basis.
	The fair values of the Company’s financial assets and liabilities measured on a recurring basis, as of September 30, 2014 and December 31, 2013, are as follows:
			Total		Quoted Prices in		Significant Other		Significant
					Active Markets for		Observable Inputs		Unobservable Inputs
					Identical Assets		(Level 2)		(Level 3)
					(Level 1)
			(in thousands)
	Cash equivalents:
	Money market accounts		$	40,013	$	40,013	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit			1,495		1,495		—		—
	Fair value measurement as of September 30, 2014		$	41,508	$	41,508	$	—	$	—
	Cash equivalents:
	Money market accounts		$	41,183	$	41,183	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit			1,325		1,325		—		—
	Fair value measurement as of December 31, 2013		$	42,508	$	42,508	$	—	$	—
	The fair value of the Company’s cash equivalents includes money market funds and certificates of deposit with maturities of one year or less. Short-term investments consist of certificate of deposit accounts that expire within 12 months for which market prices are readily available. The restrictions placed on the certificate of deposit accounts have a negligible effect on the fair value of these financial assets; these funds are restricted to meet the Company’s obligation for workers’ compensation claims.
	The Company adopted the required fair value measurements and disclosures provisions related to nonfinancial assets and liabilities. These assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include long-lived assets, goodwill, and intangible assets for which the fair value of assets is determined as part of the related impairment test. As of September 30, 2014 and December 31, 2013, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

Note_9_Goodwill_and_Intangible

Note 9 - Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	9. Goodwill and Intangible Assets
	Intangible assets include product rights, trademarks, patents, land-use rights, and goodwill. The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:
		Weighted-Average		Original Cost		Accumulated Amortization		Net Book Value
		Life (Years)
				(in thousands)
	Definite-lived intangible assets
	Product rights		12	$	27,134	$	20,451	$	6,683
	Patents		10		293		71		222
	Trademarks		11		19		13		6
	Land-use rights		39		2,540		206		2,334
	Other intangible assets		1		505		505		—
	Subtotal		12		30,491		21,246		9,245
	Indefinite-lived intangible assets
	Trademark		*		29,225		—		29,225
	Goodwill		*		4,649		—		4,649
	AFP customers		*		102		—		102
	Subtotal		*		33,976		—		33,976
	As of September 30, 2014		*	$	64,467	$	21,246	$	43,221
		Weighted-Average		Original Cost		Accumulated Amortization		Net Book Value
		Life (Years)
				(in thousands)
	Definite-lived intangible assets
	Product rights		12	$	27,134	$	19,114	$	8,020
	Patents		10		298		50		248
	Trademarks		11		19		13		6
	Land-use rights		39		2,540		156		2,384
	Other intangible assets		1		505		505		—
	Subtotal		11		30,496		19,838		10,658
	Indefinite-lived intangible assets
	Trademark		*		29,225		—		29,225
	Goodwill		*		280		—		280
	Subtotal		*		29,505		—		29,505
	As of December 31, 2013		*	$	60,001	$	19,838	$	40,163
	* Intangible assets with indefinite lives have an undeterminable average life.
	Goodwill acquired during the nine months ended September 30, 2014 is wholly related to the Merck API Transaction (see Note 3).
	Primatene Mist Trademark
	In January, 2009, the Company acquired the exclusive rights to the trademark, domain name, website and domestic marketing, distribution and selling rights related to Primatene Mist, an over-the-counter bronchodilator product, for a total consideration of $29.2 million, which is its carrying value as of September 30, 2014.
	In determining the useful life of the trademark, the Company considered the following: the expected use of the intangible; the longevity of the brand; the legal, regulatory and contractual provisions that affect their maximum useful life; the Company’s ability to renew or extend the asset’s legal or contractual life without substantial costs; effects of the regulatory environment; expected changes in distribution channels; maintenance expenditures required to obtain the expected future cash flows from the asset; and considerations for obsolescence, demand, competition and other economic factors.
	As a result of environmental concerns about Chlorofluorocarbons, or CFCs, the FDA issued a final ruling on January 16, 2009 that required the CFC formulation of its Primatene Mist product to be phased out by December 31, 2011. The former formulation of Primatene Mist contained CFCs as a propellant; however, the Company intends to use the trademark for a future version of Primatene Mist that utilizes hydrofluoroalkane, or HFA, as a propellant.
	In 2013, the Company filed a new drug application, or NDA, for Primatene Mist HFA.  In May 2014, the Company received a complete response letter, or CRL, from the FDA, which requires additional non-clinical information, label revisions and follow-up studies (label comprehension, behavioral and actual use) to assess consumers’ ability to use the device correctly to support approval of the product in the over-the-counter setting. Additionally, the CRL noted current Good Manufacturing Practices, or cGMP, deficiencies in a recent inspection of the Company’s API supplier’s manufacturing facility, which produces epinephrine, and indicated that the Company’s NDA could not be approved until these issues were resolved. Subsequent to the receipt of the CRL, the supplier notified the Company that the cGMP deficiencies were satisfactorily resolved.  Accordingly, the Company believes this condition for approval has been satisfied. The Company met with the FDA in October 2014 to discuss preliminary data results and to clarify the FDA requirements for further studies.  The Company is in the process of generating the remaining data required by the CRL and will submit an NDA Amendment that it believes will address the FDA’s concerns. However, there can be no guarantee that any amendment to the Company’s NDA will result in timely approval of the product or approval at all.
	Based on the Company’s filed version of Primatene Mist HFA, the Company’s plan to submit an NDA amendment to address the FDA’s concerns, the long history of the Primatene Mist trademark (marketed since 1963) and the Company’s perpetual rights to the trademark, the Company has determined that the trademark has an indefinite useful life. If the HFA version is approved by the FDA, it will be marketed under the same trade name; therefore, an impairment charge would not be required.

Note_10_Inventories

Note 10 - Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	10. Inventories
	Inventories are stated at the lower of cost or market, using the first-in, first-out method. Provisions are made for slow-moving, unsellable or obsolete items. Inventories consist of currently marketed products and products manufactured under contract.  Inventories consist of the following:
		September 30,			December 31,
		2014			2013
		(in thousands)
	Raw materials and supplies	$	42,049		$	34,470
	Work in process		23,558			14,698
	Finished goods		23,430			26,501
	Total inventory		89,037			75,669
	Less reserve for excess and obsolete inventories		(985	)		(5,753	)
	Total inventory, net	$	88,052		$	69,916

Note_11_Property_Plant_and_Equ

Note 11 - Property, Plant, and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	11.  Property, Plant, and Equipment
	Property, plant, and equipment consist of the following:
		September 30,			December 31,
		2014			2013
		(in thousands)
	Building	$	66,764		$	58,898
	Leasehold improvements		23,942			23,834
	Land		7,073			5,805
	Machinery and equipment		104,176			93,617
	Furniture, fixtures, and automobiles		11,171			9,355
	Construction in progress		20,319			15,685
	Total property, plant, and equipment		233,445			207,194
	Less accumulated depreciation and amortization		(99,333	)		(90,575	)
	Total property, plant, and equipment, net	$	134,112		$	116,619
	As of September 30, 2014 and December 31, 2013, the Company had $3.2 million and $3.4 million in capitalized manufacturing equipment that is intended to be used specifically for the manufacture of Primatene Mist HFA, respectively. The Company will continue to monitor developments with the FDA as it relates to its Primatene Mist HFA indefinite lived intangible asset in determining if there is an impairment of these related fixed assets (see Note 9).

Note_12_Impairment_of_LongLive

Note 12 - Impairment of Long-Lived Assets	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Asset Impairment Charges [Text Block]	'
	12. Impairment of Long-Lived Assets
	All of the Company’s impairments relate primarily to the write-off of certain manufacturing equipment related to abandoned projects. For the three months ended September 30, 2014, the Company recorded an immaterial amount of impairment loss.  For the nine months ended September 30, 2014, the Company recorded an impairment loss of $0.4 million. For the three and nine months ended September 30, 2013, the Company recorded an immaterial amount of impairment loss.

Note_13_Debt

Note 13 - Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	13. Debt
	Debt consists of the following:
		September 30,		December 31,
		2014		2013
		(in thousands)
	Loans with East West Bank
	Mortgage payable due January 2016	$	3,927	$	4,041
	Mortgage payable due September 2016		2,308		2,364
	Equipment loan due November 2014		145		783
	Line of credit facility due March 2016		—		—
	Equipment loan due April 2017		3,222		4,103
	Line of credit facility due January 2019		—		—
	Loans with Cathay Bank
	Mortgage payable due April 2021		4,571		4,624
	Revolving line of credit due May 2016		—		15,000
	Acquisition loan due April 2019		21,323		—
	Payment obligation to Merck		14,740		—
	Equipment under Capital Leases		1,113		1,258
	Total debt and capital leases		51,349		32,173
	Less current portion of long-term debt and capital leases		10,078		22,104
	Long-term debt, net of current portion and capital leases	$	41,271	$	10,069
	Loans with East West Bank
	Mortgage Payable—Due January 2016
	In December 2010, the Company refinanced an existing mortgage term loan, which had a principal balance outstanding of $4.5 million at December 31, 2010. The loan is payable in monthly installments with a final balloon payment of $3.8 million. The loan is secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex, as well as one of its buildings at its Chino, California, complex. The loan bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 5.00%, and matures in January 2016.
	Mortgage Payable—Due September 2016
	In September 2006, the Company entered into a mortgage term loan in the principal amount of $2.8 million, which matures in September 2016. The loan is payable in monthly installments with a final balloon payment of $2.2 million plus interest. The loan is secured by one of the buildings at the Company’s Rancho Cucamonga, California, headquarters complex. The variable interest rate is equal to the three-month LIBOR plus 2.50%.
	Equipment Loan—Due November 2014
	In May 2009, the Company entered into an $8.0 million revolving credit facility that converted the outstanding principal balance of $3.2 million in November 2010 into an equipment loan. Borrowings under the facility are secured by equipment purchased with debt proceeds. The facility bears interest at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 5.00%, and matures in November 2014.
	Line of Credit Facility—Due March 2016
	In March 2012, the Company entered into a $10.0 million line of credit facility. Borrowings under the facility are secured by inventory and accounts receivable.  Borrowings under the facility bear interest at the prime rate as published by The Wall Street Journal. This facility was to mature in July 2014.  In April 2014, the Company extended the maturity date to March 2016.  As of September 30, 2014, the Company did not have any amounts outstanding under this facility.
	Equipment Loan—Due April 2017
	In March 2012, the Company entered into an $8.0 million revolving credit facility that converted the outstanding principal balance of $4.9 million in March 2013 into an equipment loan. Borrowings under the facility are secured by equipment purchased with debt proceeds. Borrowings under the facility bear interest at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 3.50%. This facility matures in April 2017.
	Line of Credit Facility—Due January 2019
	In July 2013, the Company entered into an $8.0 million line of credit facility.  Borrowings under the facility are secured by equipment. The facility bears interest at the prime rate as published in The Wall Street Journal plus 0.25% and matures in January 2019.  As of September 30, 2014, the Company did not have any amounts outstanding under this facility.
	Loans with Cathay Bank
	Mortgage Payable—Due April 2021
	In March 2007, the Company entered into a mortgage term loan in the principal amount of $5.3 million, which matured in March 2014.  In April 2014, the Company refinanced the mortgage term loan, which had a principal balance outstanding of $4.6 million.  The loan is payable in monthly installments of $28.1 thousand with a final balloon payment of $3.9 million.  The loan is secured by the building at the Company’s Canton, Massachusetts, location and bears interest at a fixed rate of 5.42% and matures in April 2021.  As of September 30, 2014, the loan had a fair value of $4.9 million, compared to a book value of $4.6 million. The fair value of the loan was determined by using the interest rate associated with the Company’s mortgage loans with similar terms and collateral that has variable interest rates. The fair value of debt obligations is not measured on a recurring basis and the variable interest rate is deemed to be a Level 2 input for measuring fair value.
	Revolving Line of Credit—Due May 2016
	In April 2012, the Company entered into a $20.0 million revolving line of credit facility.  Borrowings under the facility are secured by inventory, accounts receivables, and intangibles held by the Company.  The facility bears interest at the prime rate as published by The Wall Street Journal with a minimum interest rate of 4.00%.  This revolving line of credit was to mature in May 2014.  In April 2014, the Company modified the facility to extend the maturity date to May 2016.   As of September 30, 2014, the Company did not have any amounts outstanding under this facility.
	Acquisition Loan with Cathay Bank—Due April 2019
	On April 22, 2014, in conjunction with the Merck API Transaction, the Company entered into a secured term loan with Cathay Bank as lender. The principal amount of the loan is $21.9 million and bears a variable interest rate at the prime rate as published by The Wall Street Journal, with a minimum interest rate of 4.00%. Beginning on June 1, 2014 and through the maturity date, April 22, 2019, the Company must make monthly payments of principal and interest based on the then outstanding amount of the loan amortized over a 120-month period. On April 22, 2019, all amounts outstanding under the loan become due and payable, which would be approximately $12.0 million based upon an interest rate of 4.00%. The loan is secured by 65% of the issued and outstanding shares of stock in AFP and certain assets of the Company, including accounts receivable, inventory, certain investment property, goods, deposit accounts, and general intangibles but not including the Company’s equipment and real property.
	The loan includes customary restrictions on, among other things, the Company’s ability to incur additional indebtedness, pay dividends in cash or make other distributions in cash, make certain investments, create liens, sell assets, and make loans. The loan also includes customary events of defaults, the occurrence and continuation of any of which provide Cathay Bank the right to exercise remedies against the Company and the collateral securing the loan. These events of default include, among other things, the Company’s failure to pay any amounts due under the loan, the Company’s insolvency, the occurrence of any default under certain other indebtedness or material agreements, and a final judgment against the Company that is not discharged in 30 days.
	Payment Obligation
	Merck—Due December 2017
	On April 30, 2014, in conjunction with the Merck API Transaction, the Company entered into a commitment obligation with Merck, in the principal amount of €11.6 million, or $16.0 million, subject to currency exchange fluctuations.  The terms of the purchase price include annual payments over four years and bear a fixed interest rate of 3.00%. The final payment to Merck relating to this obligation is due December 2017.
	As of September 30, 2014, the payment obligation had a book value of $14.7 million, which approximates fair value.  The fair value of the payment obligation was determined by using the interest rate associated with the Company’s acquisition loan with Cathay Bank that bears a variable interest rate at the prime rate as published by the Wall Street Journal, with a minimum interest rate of 4.00%.  The fair value of the debt obligation is not measured on a recurring basis and the variable interest rate is deemed to be a Level 2 input for measuring fair value.
	Covenants
	At September 30, 2014 and December 31, 2013, the Company was in compliance with its debt covenants, which include a minimum current ratio, minimum debt service coverage, minimum tangible net worth, and maximum debt-to-effective-tangible-net-worth ratio, computed on a consolidated basis in some instances and on a separate-company basis in others.
	Equipment under Capital Leases
	The Company entered into leases for certain equipment under capital leasing arrangements, which will expire at various times through 2018. The cost of equipment under capital leases was $1.6 million and $1.5 million at September 30, 2014 and December 31, 2013, respectively.
	The accumulated amortization of equipment under capital leases was $0.4 million and $0.2 million at September 30, 2014 and December 31, 2013, respectively. Amortization of assets recorded under capital leases is included in depreciation and amortization expense in the accompanying consolidated financial statements.

Note_14_Income_Taxes

Note 14 - Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	14. Income Taxes
	The following table sets forth the Company’s income tax provision for the periods indicated:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014				2013
		(in thousands)
	Income (loss) before taxes		$	(7,984	)		$	335			$	(12,331	)		$	14,445
	Income tax provision (benefit)			(2,605	)			494				(4,153	)			4,412
	Net income (loss)		$	(5,379	)		$	(159	)		$	(8,178	)		$	10,033
	Income tax provision (benefit) as a percentage of income before income taxes			(32.6	%)			147.5	%			(33.7	%)			30.5	%
	The Company’s income tax benefit for the three and nine months ended September 30, 2014 was (32.6%) and (33.7%) of income before income taxes, respectively.  The blended effective income tax rate expected for the year ended December 31, 2014 is 33.8%.  This tax provision rate factors in various domestic deductions and the impact of foreign operations on the Company’s overall tax rate. The Company’s income tax provision rate of 147.5% and 30.5% during the three and nine months ended September 30, 2013, respectively, factored in similar deductions as well as the impact of foreign operations.
	Undistributed Earnings (Losses) from Foreign Operations
	Deferred income taxes have not been provided on the accumulated undistributed losses of the Company’s foreign subsidiaries of approximately $9.8 million and $5.0 million as of September 30, 2014 and December 31, 2013, respectively. The Company does not have plans to repatriate its foreign earnings to the U.S. as dividends.

Note_15_Stockholders_Equity

Note 15 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	15. Stockholders' Equity
	A summary of the changes in stockholders’ equity for the nine months ended September 30, 2014 consisted of the following:
			Nine Months Ended
			September 30,
			2014
			(in thousands)
	Stockholders’ equity as of December 31, 2013		$	251,545
	Net loss			(8,178	)
	Accumulated other comprehensive loss			(1,803	)
	Common stock issued through initial public offering			38,018
	Common stock issued to employees, net of shares withheld			(485	)
	Cost related to public offering			(3,358	)
	Exercise of stock options			701
	Nonemployee share-based compensation expense			728
	Employee share-based compensation expense			5,952
	Stockholders’ equity as of September 30, 2014		$	283,120
	Accumulated Other Comprehensive Loss
	For the Company’s recently acquired subsidiary in France, the Euro, which is the local currency in France, has been determined to be the functional currency.  The results of the Company’s French subsidiary’s operations are translated to U.S. dollars at the average exchange rates during the period.  Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date.  Equity is translated at the prevailing rate of exchange at the date of the equity transaction.  Translation adjustments are reflected in stockholders’ equity and are included as a component of Accumulated other comprehensive loss for the three and nine months ended September 30, 2014.
	Common Stock
	In June 2014, the Company completed an Initial Public Offering in which the Company sold 5,840,000 shares of its common stock, which included 1,200,000 shares of the Company’s common stock pursuant to the underwriters’ exercise of their over-allotment option, at a price to the public of $7.00 per share, resulting in gross proceeds of $40.9 million.  In connection with the offering, the Company paid $6.2 million in underwriting discounts, commissions, and offering costs, resulting in net proceeds of $34.7 million.
	Share-Based Award Activity and Balances
	The Company accounts for share-based compensation payments in accordance with FASB-issued accounting standards, which require measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees, directors, and nonemployees. Under these standards, the fair value of share-based payment awards is estimated at the grant date using an option-pricing model and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of share-based awards and recognizes share-based compensation cost over the vesting period using the straight-line single option method.  Non-vested stock options held by non-employees are revalued using the Company’s estimate of fair value at each balance sheet date.
	The Company did not grant any stock options during the three months ended September 30, 2014.  The weighted-averages for key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2014 and the three and nine months ended September 30, 2013 are as follows:
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2014				2013				2014				2013
	Average volatility			—				28.3	%			29.9	%			28.5	%
	Risk-free interest rate			—				1.2	%			1.7	%			1.2	%
	Weighted-average expected life in years			—				4.4				5				4.4
	Dividend yield rate			—				0	%			0	%			0	%
	Stock Options
	A summary of option activity under all plans for the nine months ended September 30, 2014 is presented below:
			Options				Weighted-				Weighted-				Aggregate
							Average				Average				Intrinsic
							Exercise				Remaining				Value(1)
							Price				Contractual
											Term (Years)
															(in thousands)
	Outstanding as of December 31, 2013			10,771,755			$	15.39
	Options granted			1,661,862				15.04
	Options exercised			(65,000	)			10.79
	Options cancelled			(60,198	)			12.11
	Options expired			(796,988	)			18.86
	Outstanding as of September 30, 2014			11,511,431			$	15.14				4.87			$	1,975
	Exercisable as of September 30, 2014			5,732,361			$	17.27				3.6			$	806
		-1	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s common stock for those awards that have an exercise price below the estimated fair value at September 30, 2014.
	For the three and nine months ended September 30, 2014, the Company recorded stock option expense related to employees under all plans of $2.0 million and $5.1 million, respectively. For the three and nine months ended September 30, 2013, the Company recorded stock option expense related to employees under all plans of $2.2 million and $4.5 million, respectively.
	Information relating to option grants and exercises is as follows:
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014				2013
		(in thousands, except per share data)
	Weighted-average grant date fair value		$	—			$	2.5			$	4.02			$	2.54
	Intrinsic value of options exercised			283				4				144				(1	)
	Cash received			130				38				701				51
	Total fair value of the options vested during the year			3,510				3,203				4,324				4,056
	A summary of the status of the Company’s nonvested options as of September 30, 2014, and changes during the nine months ended September 30, 2014, are presented below:
			Options				Weighted-Average
							Grant Date
							Fair Value
	Nonvested as of December 31, 2013			5,617,554			$	3.12
	Options granted			1,661,862				4.02
	Options vested			(1,440,148	)			3
Options forfeited			(60,198	)			4.35
Nonvested as of September 30, 2014			5,779,070				3.39
As of September 30, 2014, there was $13.8 million of total unrecognized compensation cost, net of forfeitures, related to nonvested stock option based compensation arrangements granted under the Company’s 2005 Equity Incentive Award Plan, or the 2005 Plan. The cost is expected to be recognized over a weighted-average period of 2.5 years and will be adjusted for future changes in estimated forfeitures.
Deferred Stock Units
From 2007 through 2014, the Company granted restricted stock awards in the form of deferred stock units, or DSUs, to certain officers, consultants, and employees, either as compensation or in exchange for expiring stock options. The grantee receives one share of common stock at a specified future date for each DSU awarded. The DSUs may not be sold or otherwise transferred until certificates of common stock have been issued, recorded, and delivered to the participant. The DSUs do not have any voting or dividend rights prior to the issuance of certificates of the underlying common stock.
The Company issued DSUs that were treated as an accounting exchange for expiring stock options, whereby the fair value of the expiring stock options equaled the fair value of the DSUs at the date of the exchange. As such, the Company did not record any expense related to these award modifications.
Additionally, the Company issued DSUs to its Board of Directors and employees as compensation with a vesting period of up to five years.  The share-based expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period.  The Company recorded a total expense of $0.5 million and $1.2 million for the three and nine months ended September 30, 2014, respectively, for these DSU awards, compared to the prior year expense for the three and nine months ended September 30, 2013 of $0.2 million and $0.4 million, respectively.
As of September 30, 2014, there was $5.8 million of total unrecognized compensation cost, net of forfeitures, related to nonvested DSU-based compensation arrangements granted under the 2005 Plan. The cost is expected to be recognized over a weighted-average period of 3.4 years and will be adjusted for future changes in estimated forfeitures.
Information relating to DSU grants and deliveries is as follows:
		Total DSUs Issued				Total Fair Market
						Value of DSUs
						Issued
						as Compensation (1)
						(in thousands)
DSUs outstanding at December 31, 2013			98,495
DSUs granted			449,544			$	6,389
DSUs forfeited			(994	)
Common stock delivered			(9,497	)
DSUs surrendered for taxes			(7,774	)
DSUs outstanding at September 30, 2014			529,774
(1)	The total FMV is derived from the number of DSUs granted times the current stock price on the date of grant.

Note_16_Commitments_and_Contin

Note 16 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	16. Commitments and Contingencies
	Distribution Agreement with Actavis, Inc.
	In May 2005, the Company entered into an agreement to grant certain exclusive marketing rights for its enoxaparin product to Andrx Pharmaceuticals, Inc., or Andrx, which generally extends to the U.S. retail pharmacy market. To obtain such rights, Andrx made a non-refundable, upfront payment of $4.5 million to the Company upon execution of the agreement.  Under the agreement, the Company is paid a fixed cost per unit sold to Andrx and also shares in the gross profits (as defined) from Andrx’s sales of the product in the U.S. retail pharmacy market. In November 2006, Watson Pharmaceuticals, Inc., or Watson, acquired Andrx and all of the rights and obligations associated with the agreement. The $4.5 million upfront payment was classified as deferred revenue on the accompanying consolidated balance sheets, as there had been no amortization through December 31, 2011.
	In January 2012, the Federal Circuit Court issued a stay on the Preliminary Injunction (see Note 17) that had previously barred the Company from selling its generic enoxaparin product. This event, in addition to the Company’s product launch, establishes the beginning of the seven-year period in which Watson has the exclusive marketing rights for the Company’s enoxaparin product in the U.S. retail pharmacy market and the start of the Company’s recognition of the $4.5 million deferred revenue over this period on a straight-line basis. Watson has an option to renew the agreement for an additional three years.  As of September 30, 2014 and December 31, 2013, the balance of the deferred revenue was $2.8 million and $3.3 million, respectively.
	In January 2013, Watson adopted Actavis, Inc. as its new global name. The agreement has a term that expires in January 2019 and can be extended by Actavis for an additional three years. The agreement may only be terminated prior to the end of the term by either party in the case of a breach of contract or insolvency of the other party, by the Company if Actavis fails to purchase a minimum number of units and by Actavis if an infringement claim is made against Actavis.
	The Company manufactures its enoxaparin product for the retail market according to demand specifications of Actavis. Upon shipment of enoxaparin to Actavis, the Company recognizes product sales at an agreed transfer price and records the related cost of products sold. Based on the terms of the Company’s distribution agreement with Actavis, the Company is entitled to a share of the ultimate profits based on the eventual net revenue from enoxaparin sales by Actavis to the end user less the agreed transfer price originally paid by Actavis to the Company. Actavis provides the Company with a quarterly sales report that calculates the Company’s share of Actavis’ enoxaparin gross profit. The Company records its share of Actavis’ gross profit as a component of net revenue.
	Supply Agreement with MannKind Corporation
	On July 31, 2014, the Company entered into a supply agreement with MannKind Corporation, or MannKind, pursuant to which AFP will manufacture for and supply to MannKind certain quantities of recombinant human insulin, or Insulin, for use in MannKind’s product AFREZZA®. Under the terms of the supply agreement, AFP will be responsible for manufacturing the Insulin in accordance with MannKind’s specifications and agreed-upon quality standards.  MannKind has agreed to purchase annual minimum quantities of Insulin under the supply agreement of an aggregate of approximately €120.1 million, or approximately $152.3 million, in calendar years 2015 through 2019.  MannKind may request to purchase additional quantities of Insulin over such annual minimum quantities.
	MannKind paid a non-refundable reservation fee to the Company in the amount of €11.0 million, or approximately $14.0 million.  Under the agreement, the non-refundable reservation fee is considered as partial payment for the purchase commitment quantity for 2015. The Company classified the amount as deferred revenue.
	Unless earlier terminated, the term of the supply agreement expires on December 31, 2019 and can be renewed for additional, successive two-year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two-year term.  MannKind and the Company each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy, or insolvency of the other party. In addition, MannKind may terminate the supply agreement upon two years’ prior written notice to the Company without cause or upon 30 days prior written notice to the Company if a controlling regulatory authority withdraws approval for AFREZZA®; provided, however, in the event of a termination pursuant to either of these scenarios, the provisions of the supply agreement require MannKind to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.
	Operating Lease Agreements
	The Company leases real and personal property, in the normal course of business, under various non-cancelable operating leases. The Company, at its option, can renew a substantial portion of its leases, at the market rate, for various renewal periods ranging from one to six years. Rental expense under these leases for the three and nine months ended September 30, 2014 was approximately $0.8 million and $2.3 million, respectively, compared to the prior year three and nine months ended September 30, 2013 when the expense was approximately $0.8 million and $2.4 million, respectively.
	Purchase Commitments
	As of September 30, 2014, the Company has entered into commitments to purchase equipment and raw materials for an aggregate of $7.7 million. The Company anticipates that most of these commitments will be fulfilled by 2015.
	The Company has entered into agreements with a Chinese governmental entity to acquire land-use rights to real property in Nanjing, China. Under the terms of these agreements, the Company has committed to invest capital in its wholly-owned subsidiary, ANP, and to develop these properties as an API manufacturing facility for the Company’s pipeline. In conjunction with these agreements, ANP modified its business license on July 3, 2012 to increase its authorized capital. As of September 30, 2014, the Company had invested approximately $41.0 million in ANP of its registered capital commitment of $61.0 million. The Company has committed to invest an additional $20.0 million in ANP, which is currently due by December 2014. This requirement to invest in ANP will result in cash being transferred from the U.S. parent company to ANP.
	Per these agreements, in January 2010, the Company acquired certain land-use rights with a carrying value of $1.2 million.  In addition, the Company purchased additional land-use rights in November 2012 for $1.3 million.  The Company is committed to spend approximately $15.0 million in land development.  The agreements require the construction of fixed assets on the property and specified a timetable for the construction of these fixed assets. The current pace of development of the property is behind the schedules described in the purchase agreements and, per the purchase agreement, potential monetary penalties could result if the development is delayed or not completed in accordance with the guidelines stated in the purchase agreements. During the three months ended September 30, 2014, the Company invested $3.2 million to fund the Company’s research and development pipeline.
	Government Regulation
	The Company’s products and facilities are subject to regulation by a number of federal and state governmental agencies. The Food and Drug Administration, or FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of the Company’s products.  The Drug Enforcement Administration, or DEA, maintains oversight over the Company’s products that are considered controlled substances.
	On March 31, 2014 through April 4, 2014, the Company’s facility in Nanjing, China was subject to an inspection by the FDA. The inspection resulted in multiple observations on Form 483, an FDA form on which deficiencies are noted after an FDA inspection. The Company responded to those observations on April 25, 2014 and has implemented the required corrective actions. The Company believes that it addressed all of the observations, and the Company responded to the FDA with data supporting its actions in October 2014.
	On March 31, 2014 through April 3, 2014, the Company’s facility in Canton, MA was subject to a preapproval inspection by the FDA relating to the Company’s NDA for Primatene. The inspection did not result in any observations on Form 483.
	From July 9, 2014 through August 8, 2014, the Company’s facility in Rancho Cucamonga, CA was subject to an inspection by the FDA. The inspection included a review of current Good Manufacturing Practices, preapproval inspections for two ANDAs currently being reviewed by the FDA, and a review of post-market adverse drug events. The inspections resulted in multiple observations on Form 483. The Company responded to those observations on August 25, 2014.  The Company believes that its responses to the Form 483 will satisfy the FDA and that no significant further actions will be necessary.
	From August 27, 2014 through September 12, 2014, the Company’s IMS facility in South El Monte, CA was subject to a current Good Manufacturing Practices inspection by the FDA.  The inspections resulted in multiple observations on Form 483. The Company responded to those observations on October 3, 2014.  The Company believes that its responses to the Form 483 will satisfy the FDA and that no significant further actions will be necessary.
	AFP Environmental Indemnification
	Prior to the Merck API Transaction, Merck notified the Company of several items it had identified as part of its own internal auditing that relate to potential minor environmental issues.  The Company understands from Merck that it identified these items because the items were not in alignment with Merck’s own internal policies and procedures, and not because any of the items are in violation of any French environmental law or regulation.  Under a letter of understanding, or LOU, dated April 30, 2014, Merck has agreed to pay for the remediation costs up to certain dollar limits, and to date, all estimates suggest the cost of conducting the remediation will be less than those dollar limits.  The LOU also includes an indemnification provision that would require the Company to indemnify Merck for liability that might arise from performance of the remediation work itself but not for other types of liability.

Note_17_Litigation

Note 17 - Litigation	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Legal Matters and Contingencies [Text Block]	'
	17. Litigation
	Enoxaparin Patent Litigation
	In September 2011, Momenta Pharmaceuticals, Inc, or Momenta, a Boston-based pharmaceutical company, and Sandoz Inc, or Sandoz, the generic division of Novartis, initiated litigation against the Company for alleged patent infringement of two patents related to testing methods for batch release of enoxaparin, which the Company refers to as the “‘886 patent” and the “‘466 patent.” The lawsuit was filed in the United States District Court for the District of Massachusetts, or the District Court. In October 2011, the District Court issued a preliminary injunction barring the Company from selling its generic enoxaparin product and also requiring Momenta and Sandoz to post a $100.1 million bond. The preliminary injunction was stayed by the United States Court of Appeals for the Federal Circuit, or Federal Circuit, in January 2012, and reversed by the Federal Circuit in August 2012.
	In January 2013, the Company moved for summary judgment of non-infringement of both patents. Momenta and Sandoz withdrew their allegations as to the ‘466 patent, and in July 2013, the District Court granted the Company’s motion for summary judgment of non-infringement of the ‘886 patent and denied Momenta and Sandoz’s motion for leave to amend infringement contentions. On January 24, 2014, the District Court judge entered final judgment in the Company’s favor on both patents. Momenta and Sandoz also filed a motion to collect attorney’s fees and costs relating to a discovery motion which the District Court granted. The parties have briefed the amount of attorney’s fees that should be imposed, which the Company believes should not exceed an amount of approximately $40.0 thousand. On January 30, 2014, Momenta and Sandoz filed a notice of appeal to the Federal Circuit appealing the court’s final judgment including summary judgment denying Momenta and Sandoz’s motion for leave to amend their infringement contentions. The Company intends to attempt to collect the $100.1 million bond posted by Momenta and Sandoz following the appeal. Momenta filed its opening appeal brief on June 27, 2014, and the Company filed its responding brief on September 25, 2014. Under the current briefing schedule for the appeal, Momenta’s reply brief is due by November 13, 2014. A date for oral argument has not yet been set by the Federal Circuit.
	False Claims Act Litigation
	In January 2009, the Company filed a qui tam complaint in the U.S. District Court for the Central District of California alleging that Aventis Pharma S.A., or Aventis, through its acquisition of a patent through false and misleading statements to the U.S. Patent and Trademark Office, as well as through false and misleading statements to the FDA, overcharged the federal and state governments for its Lovenox product. If the Company is successful in this litigation, it could be entitled to a portion of any damage award that the government ultimately may recover from Aventis. In October 2011, the District Court unsealed the Company’s complaint. Since the complaint was unsealed, this case has steadily progressed and remains pending with discovery underway.
	On February 28, 2014, Aventis filed a motion for summary judgment on the issue of the adequacy of the Company’s notice letter to the government, and the District Court denied Aventis’ motion for summary judgment in a final order it issued on May 12, 2014. On June 9, 2014, at Aventis’ request, the District Court issued an order certifying for appeal its order denying Aventis’ motion for summary judgment. On June 9, 2014, Aventis filed with the United States Court of Appeals for the Ninth Circuit a petition for permission to appeal the District Court’s denial of Aventis’ motion for summary judgment, and the Company filed an opposition to Aventis’ petition on June 19, 2014. On August 22, 2014, the Court of Appeals granted Aventis’ petition. Under the current schedule, Aventis’ opening appeal brief is due by December 1, 2014, and the Company’s answering brief is due by January 2, 2015.
	The District Court set an evidentiary hearing for July 7, 2014 on the “original source” issue, a key element under the False Claims Act. The evidentiary hearing was conducted as scheduled, from July 7, 2014 through July 10, 2014. The Company filed its post-hearing brief on August 11, 2014, Aventis filed its post-hearing brief on September 10, 2014, and the Company filed its reply brief on September 24, 2014. The District Court conducted a hearing for closing argument on the original source issue on October 10, 2014. The original source issue currently is under submission with the District Court.
	Other Litigation
	The Company is also subject to various other claims and lawsuits arising in the ordinary course of business. In the opinion of management, the ultimate resolution of these matters is not expected to have a materially adverse effect on its financial position, results of operations, or cash flows; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

Note_18_Subsequent_Events

Note 18 - Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	18. Subsequent Events
	On November 6, 2014, the Company’s Board of Directors authorized a $10.0 million share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.
	Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the Securities and Exchange Commission.
	The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	All significant intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. The unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X. Some information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles, or GAAP, have been condensed or omitted pursuant to those rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.
	The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: International Medication Systems, Limited, or IMS; Amphastar Laboratories, Inc.; Armstrong Pharmaceuticals, Inc., or Armstrong; Amphastar Nanjing Pharmaceuticals Co., Ltd., or ANP; and Amphastar France Pharmaceuticals, S.A.S., or AFP.
Reclassification, Policy [Policy Text Block]	'
	Amounts reclassified
	Certain amounts in the prior years’ financial statements have been reclassified to conform to the current year presentation. These reclassifications relate to the Company’s accounting for accrued chargebacks, which was originally included on the Company’s consolidated balance sheets as a liability and is now reflected as a reduction to accounts receivable. These reclassifications have no impact on net income or cash flows.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for doubtful accounts and discounts, liabilities for product returns and chargebacks, reserves for excess or unsellable inventory, impairment of long-lived and intangible assets and goodwill, self-insured claims, workers’ compensation liabilities, litigation reserves, stock price volatilities for share-based compensation expense, fair market values of the Company’s common stock, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency
	The functional currency of the Company and its domestic and Chinese subsidiaries is the U.S. dollar, or USD.  The Company’s Chinese subsidiary, ANP, maintains its books of record in Chinese Yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign exchange gains and losses are reflected in the Company’s statement of operations.  The Company’s French subsidiary, AFP, maintains its books of record in Euros, which is the local currency in France and has been determined to be its functional currency. These books are translated to USD at the average exchange rates during the period.  Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date.  Equity is translated at the prevailing rate of exchange at the date of the equity transactions.  Translation adjustments are reflected in stockholders’ equity and are included as a component of other comprehensive income (loss).  Additionally, the Company does not undertake hedging transactions to cover its foreign currency exposure.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive Income (Loss)
	For the three and nine months ended September 30, 2014, the Company includes its foreign currency translation adjustment as part of its comprehensive loss as a result of establishing the Company’s subsidiary, AFP, in France.  For the three and nine months ended September 30, 2013, net income (loss) equaled total comprehensive income (loss).
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Financial Instruments
	The carrying amounts of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. A majority of the Company’s long-term obligations consist of variable rate debt and their carrying value approximates fair value. Their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. However, the Company has one fixed-rate, long-term mortgage for which the carrying value differs from the fair value and is not remeasured on a recurring basis (see Note 13).
Income Tax, Policy [Policy Text Block]	'
	Deferred Income Taxes
	The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company has adopted the with-and-without methodology for determining when excess tax benefits from the exercise of share-based awards are realized. Under the with-and-without methodology, current year operating loss deductions and prior-year operating loss carryforwards are deemed to be utilized prior to the utilization of current-year excess tax benefits from share-based awards.
Business Combinations Policy [Policy Text Block]	'
	Business Combinations
	Business combinations are accounted for in accordance with Accounting Standards Codification, or ASC 805, Business Combinations, using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Under the acquisition method of accounting, the Company will identify the acquirer and the closing date and apply applicable recognition principles and conditions.
	Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or FASB, issued an Accounting Standard Update to the accounting guidance to address the diversity in practice related to the financial statement presentation of unrecognized tax benefits as either a reduction of a deferred tax asset or a liability when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.
	In April 2014, the FASB issued an accounting standards update that raises the threshold for disposals to qualify as discontinued operations and allows companies to have significant continuing involvement with and continuing cash flows from or to the discontinued operation. It also requires additional disclosures for discontinued operations and new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. This guidance will be effective for fiscal years beginning after December 15, 2014, which will be the Company's fiscal year 2015, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2016, which will be the Company's fiscal year 2017. The Company has not yet evaluated the potential impact of adopting the guidance on the Company's consolidated financial statements.
	In June 2014, the FASB issued an accounting standards update that requires a performance target that affects vesting of a share-based payment award and that could be achieved after the requisite service period to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized over the required service period, if it is probable that the performance target will be achieved. This guidance will be effective for fiscal years beginning after December 15, 2015, which will be the Company's fiscal year 2016, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements.
	In August 2014, the FASB issued an accounting standards update that will require management to evaluate if there is substantial doubt about the Company’s ability to continue as a going concern and, if so, to disclose this in both interim and annual reporting periods.  This guidance will become effective for the Company’s annual filing for the period ending December 31, 2016 and interim periods thereafter, and allows for early adoption.  The Company does not expect the adoption of the guidance will have a material impact on the Company’s consolidated financial statements.

Note_3_Business_Acquisition_Ta

Note 3 - Business Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
		Euros			U.S.
					Dollars
		(in thousands)
	At Closing, April 2014	€	13,252		$	18,352
	Dec-14		4,899			6,214
	Dec-15		3,186			4,041
	Dec-16		3,186			4,041
	Dec-17		500			634
		€	25,023		$	33,282
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
		Fair Value
		Euros			U.S.
					Dollars
		(in thousands)
	Inventory	€	15,565		$	21,554
	Real property		4,800			6,647
	Machinery & equipment		6,800			9,417
	Intangibles		80			111
	Goodwill		3,155			4,369
	Total assets acquired	€	30,400		$	42,098
	Accrued liabilities	€	2,425		$	3,358
	Deferred tax liabilities		3,155			4,369
	Total liabilities assumed		5,580			7,727
	Total fair value of consideration transferred	€	24,820		$	34,371
Business Acquisition, Pro Forma Information [Table Text Block]	'
		Nine Months Ended
		September 30,
		2014			2013
		(in thousands,
		except per share data)
	Net revenues	$	156,868		$	185,293
	Net income (loss)		(9,407	)		10,827
	Diluted net income (loss) per share	$	(0.23	)	$	0.28

Note_4_Revenue_Recognition_Tab

Note 4 - Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2014
Revenue Recognition Disclosure [Abstract]	'
Schedule of Chargeback Liability [Table Text Block]	'
		Nine Months Ended				Year Ended
		September 30,				December 31,
		2014				2013
		(in thousands)
	Beginning balance		$	18,104			$	11,898
	Provision related to sales made in the current period			118,643				213,075
	Credits issued to third parties			(124,449	)			(206,869	)
	Ending balance		$	12,298			$	18,104
Schedule of Product Returns Liability [Table Text Block]	'
		Nine Months Ended				Year Ended
		September 30,				December 31,
		2014				2013
		(in thousands)
	Beginning balance		$	4,592			$	2,673
	Provision for product returns			(261	)			2,711
	Credits issued to third parties			(1,042	)			(792	)
	Ending balance		$	3,289			$	4,592

Note_5_Income_Loss_Per_Share_T

Note 5 - Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
		(in thousands, except per share data)
	Basic and dilutive numerator:
	Net income (loss)	$	(5,379	)	$	(159	)	$	(8,178	)	$	10,033
	Denominator:
	Common shares outstanding		44,642			38,707			41,058			38,699
	Contingently issuable shares - vested DSUs		2			2			2			9
	Weighted-average common shares outstanding—basic		44,644			38,709			41,060			38,708
	Net effect of dilutive securities:
	Stock options		—			—			—			63
	Contingently issuable shares – nonvested DSUs		—			—			—			77
	Weighted-average common shares outstanding—diluted		44,644			38,709			41,060			38,848
	Net income (loss) per common share—basic	$	(0.12	)	$	0		$	(0.20	)	$	0.26
	Net income (loss) per common share—diluted	$	(0.12	)	$	0		$	(0.20	)	$	0.26

Note_6_Segment_Reporting_Table

Note 6 - Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
			Three Months Ended							Nine Months Ended
			September 30,							September 30,
			2014				2013			2014				2013
			(in thousands)
	Net revenues:
	Finished pharmaceutical products		$	53,729			$	59,318		$	148,500			$	174,805
	API			5,982				—			6,084				—
	Total net revenues			59,711				59,318			154,584				174,805
	Gross Profit:
	Finished pharmaceutical products			12,122				20,280			39,592				67,327
	API			(331	)			—			(296	)			—
	Total gross profit			11,791				20,280			39,296				67,327
	Operating expenses			19,608				20,054			50,255				52,767
	Income (loss) from operations			(7,817	)			226			(10,959	)			14,560
	Non-operating income (expenses)			(167	)			109			(1,372	)			(115	)
	Income (loss) before income taxes		$	(7,984	)		$	335		$	(12,331	)		$	14,445
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	'
		Net Revenue							Net Revenue								Long-Lived Assets
		Three Months Ended							Nine Months Ended								September 30,			December 31,
		September 30,							September 30,
		2014				2013			2014				2013				2014			2013
		(in thousands)
	U.S.		$	53,729			$	59,318		$	148,500			$	174,805			$	98,744		$	99,398
	China			—				—			—				—				21,011			17,221
	France			5,982				—			6,084				—				14,357			—
	Total		$	59,711			$	59,318		$	154,584			$	174,805			$	134,112		$	116,619

Note_7_Customer_and_Supplier_C1

Note 7 - Customer and Supplier Concentration (Tables)	9 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		% of Total Accounts						% of Net						% of Net
		Receivable						Revenue						Revenue
		September 30,			December 31,			Three Months Ended						Nine Months Ended
								September 30,						September 30,
		2014			2013			2014			2013			2014			2013
	Actavis, Inc.		31	%		44	%		35	%		32	%		33	%		34	%
	AmerisourceBergen		10	%		11	%		14	%		15	%		15	%		15	%
	Cardinal Health		10	%		7	%		13	%		13	%		14	%		14	%
	McKesson		16	%		13	%		19	%		29	%		23	%		26	%

Note_8_Fair_Value_Measurements1

Note 8 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		Total		Quoted Prices in		Significant Other		Significant
				Active Markets for		Observable Inputs		Unobservable Inputs
				Identical Assets		(Level 2)		(Level 3)
				(Level 1)
		(in thousands)
	Cash equivalents:
	Money market accounts	$	40,013	$	40,013	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit		1,495		1,495		—		—
	Fair value measurement as of September 30, 2014	$	41,508	$	41,508	$	—	$	—
	Cash equivalents:
	Money market accounts	$	41,183	$	41,183	$	—	$	—
	Restricted short-term investments:
	Certificates of deposit		1,325		1,325		—		—
	Fair value measurement as of December 31, 2013	$	42,508	$	42,508	$	—	$	—

Note_9_Goodwill_and_Intangible1

Note 9 - Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
		Weighted-Average		Original Cost		Accumulated Amortization		Net Book Value
		Life (Years)
				(in thousands)
	Definite-lived intangible assets
	Product rights		12	$	27,134	$	20,451	$	6,683
	Patents		10		293		71		222
	Trademarks		11		19		13		6
	Land-use rights		39		2,540		206		2,334
	Other intangible assets		1		505		505		—
	Subtotal		12		30,491		21,246		9,245
	Indefinite-lived intangible assets
	Trademark		*		29,225		—		29,225
	Goodwill		*		4,649		—		4,649
	AFP customers		*		102		—		102
	Subtotal		*		33,976		—		33,976
	As of September 30, 2014		*	$	64,467	$	21,246	$	43,221
		Weighted-Average		Original Cost		Accumulated Amortization		Net Book Value
		Life (Years)
				(in thousands)
	Definite-lived intangible assets
	Product rights		12	$	27,134	$	19,114	$	8,020
	Patents		10		298		50		248
	Trademarks		11		19		13		6
	Land-use rights		39		2,540		156		2,384
	Other intangible assets		1		505		505		—
	Subtotal		11		30,496		19,838		10,658
	Indefinite-lived intangible assets
	Trademark		*		29,225		—		29,225
	Goodwill		*		280		—		280
	Subtotal		*		29,505		—		29,505
	As of December 31, 2013		*	$	60,001	$	19,838	$	40,163

Note_10_Inventories_Tables

Note 10 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		September 30,			December 31,
		2014			2013
		(in thousands)
	Raw materials and supplies	$	42,049		$	34,470
	Work in process		23,558			14,698
	Finished goods		23,430			26,501
	Total inventory		89,037			75,669
	Less reserve for excess and obsolete inventories		(985	)		(5,753	)
	Total inventory, net	$	88,052		$	69,916

Note_11_Property_Plant_and_Equ1

Note 11 - Property, Plant, and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		September 30,			December 31,
		2014			2013
		(in thousands)
	Building	$	66,764		$	58,898
	Leasehold improvements		23,942			23,834
	Land		7,073			5,805
	Machinery and equipment		104,176			93,617
	Furniture, fixtures, and automobiles		11,171			9,355
	Construction in progress		20,319			15,685
	Total property, plant, and equipment		233,445			207,194
	Less accumulated depreciation and amortization		(99,333	)		(90,575	)
	Total property, plant, and equipment, net	$	134,112		$	116,619

Note_13_Debt_Tables

Note 13 - Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		September 30,		December 31,
		2014		2013
		(in thousands)
	Loans with East West Bank
	Mortgage payable due January 2016	$	3,927	$	4,041
	Mortgage payable due September 2016		2,308		2,364
	Equipment loan due November 2014		145		783
	Line of credit facility due March 2016		—		—
	Equipment loan due April 2017		3,222		4,103
	Line of credit facility due January 2019		—		—
	Loans with Cathay Bank
	Mortgage payable due April 2021		4,571		4,624
	Revolving line of credit due May 2016		—		15,000
	Acquisition loan due April 2019		21,323		—
	Payment obligation to Merck		14,740		—
	Equipment under Capital Leases		1,113		1,258
	Total debt and capital leases		51,349		32,173
	Less current portion of long-term debt and capital leases		10,078		22,104
	Long-term debt, net of current portion and capital leases	$	41,271	$	10,069

Note_14_Income_Taxes_Tables

Note 14 - Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014				2013
		(in thousands)
	Income (loss) before taxes		$	(7,984	)		$	335			$	(12,331	)		$	14,445
	Income tax provision (benefit)			(2,605	)			494				(4,153	)			4,412
	Net income (loss)		$	(5,379	)		$	(159	)		$	(8,178	)		$	10,033
	Income tax provision (benefit) as a percentage of income before income taxes			(32.6	%)			147.5	%			(33.7	%)			30.5	%

Note_15_Stockholders_Equity_Ta

Note 15 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders Equity [Table Text Block]	'
			Nine Months Ended
			September 30,
			2014
			(in thousands)
	Stockholders’ equity as of December 31, 2013		$	251,545
	Net loss			(8,178	)
	Accumulated other comprehensive loss			(1,803	)
	Common stock issued through initial public offering			38,018
	Common stock issued to employees, net of shares withheld			(485	)
	Cost related to public offering			(3,358	)
	Exercise of stock options			701
	Nonemployee share-based compensation expense			728
	Employee share-based compensation expense			5,952
	Stockholders’ equity as of September 30, 2014		$	283,120
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2014				2013				2014				2013
	Average volatility			—				28.3	%			29.9	%			28.5	%
	Risk-free interest rate			—				1.2	%			1.7	%			1.2	%
	Weighted-average expected life in years			—				4.4				5				4.4
	Dividend yield rate			—				0	%			0	%			0	%
Schedule of Stock Options Roll Forward [Table Text Block]	'
			Options				Weighted-				Weighted-				Aggregate
							Average				Average				Intrinsic
							Exercise				Remaining				Value(1)
							Price				Contractual
											Term (Years)
															(in thousands)
	Outstanding as of December 31, 2013			10,771,755			$	15.39
	Options granted			1,661,862				15.04
	Options exercised			(65,000	)			10.79
	Options cancelled			(60,198	)			12.11
	Options expired			(796,988	)			18.86
	Outstanding as of September 30, 2014			11,511,431			$	15.14				4.87			$	1,975
	Exercisable as of September 30, 2014			5,732,361			$	17.27				3.6			$	806
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014				2013
		(in thousands, except per share data)
	Weighted-average grant date fair value		$	—			$	2.5			$	4.02			$	2.54
	Intrinsic value of options exercised			283				4				144				(1	)
	Cash received			130				38				701				51
	Total fair value of the options vested during the year			3,510				3,203				4,324				4,056
Schedule of Nonvested Share Activity [Table Text Block]	'
			Options				Weighted-Average
							Grant Date
							Fair Value
	Nonvested as of December 31, 2013			5,617,554			$	3.12
	Options granted			1,661,862				4.02
	Options vested			(1,440,148	)			3
	Options forfeited			(60,198	)			4.35
	Nonvested as of September 30, 2014			5,779,070				3.39
Schedule of Share-based Compensation, Activity [Table Text Block]	'
			Total DSUs Issued				Total Fair Market
							Value of DSUs
							Issued
							as Compensation (1)
							(in thousands)
	DSUs outstanding at December 31, 2013			98,495
	DSUs granted			449,544			$	6,389
	DSUs forfeited			(994	)
	Common stock delivered			(9,497	)
	DSUs surrendered for taxes			(7,774	)
	DSUs outstanding at September 30, 2014			529,774

Note_3_Business_Acquisition_De

Note 3 - Business Acquisition (Details)	0 Months Ended		0 Months Ended				0 Months Ended
In Millions, unless otherwise specified	Jun. 01, 2014	Apr. 22, 2014	Jun. 01, 2014	Apr. 22, 2014	Apr. 22, 2014	Sep. 30, 2014	Apr. 30, 2014	Apr. 30, 2014
		Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]
		Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Secured Term Loan With Cathay Bank [Member]	Minimum [Member]	USD ($)	EUR (€)
		Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]
		Minimum [Member]			USD ($)
Note 3 - Business Acquisition (Details) [Line Items]	'	'	'	'	'	'	'	'
Business Combination, Consideration Transferred	'	'	'	'	'	'	$34.40	€ 24.80
Goodwill, Purchase Accounting Adjustments	'	'	'	'	'	'	4.4	'
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities	'	'	'	'	'	'	4.4	'
Debt Instrument, Face Amount	'	'	'	'	21.9	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	4.00%	'	'	'	4.00%	'	'
Debt Instrument, Term	'120 months	'	'120 months	'	'	'	'	'
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid	'	'	'	'	$12	'	'	'
Debt Instrument Loan Collateral Percentage	'	'	'	65.00%	'	'	'	'

Note_3_Business_Acquisition_De1

Note 3 - Business Acquisition (Details) - Acquisition of Merck Sharpe & Dohme’s Payment Terms

9 Months Ended

0 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

USD ($)

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Payment at Closing, April 2014 [Member]

Payment at Closing, April 2014 [Member]

Payment Due in December 2014 [Member]

Payment Due in December 2014 [Member]

Payment Due in December 2015 [Member]

Payment Due in December 2015 [Member]

Payment Due in December 2016 [Member]

Payment Due in December 2016 [Member]

Payment Due in December 2017 [Member]

Payment Due in December 2017 [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment to Acquire Business, Gross

$18,352

$18,352

€ 13,252

$6,214

€ 4,899

$4,041

€ 3,186

$4,041

€ 3,186

$634

€ 500

$33,282

€ 25,023

Note_3_Business_Acquisition_De2

Note 3 - Business Acquisition (Details) - Acquired Assets and Liabilities Assumed	Sep. 30, 2014	Dec. 31, 2013	Apr. 30, 2014	Apr. 30, 2014
In Thousands, unless otherwise specified	USD ($)	USD ($)	Merck Sharpe & Dohme's API [Member]	Merck Sharpe & Dohme's API [Member]
			USD ($)	EUR (€)
Note 3 - Business Acquisition (Details) - Acquired Assets and Liabilities Assumed [Line Items]	'	'	'	'
Inventory	'	'	$21,554	€ 15,565
Real property	'	'	6,647	4,800
Machinery & equipment	'	'	9,417	6,800
Intangibles	'	'	111	80
Goodwill	4,649	280	4,369	3,155
Total assets acquired	'	'	42,098	30,400
Accrued liabilities	'	'	3,358	2,425
Deferred tax liabilities	'	'	4,369	3,155
Total liabilities assumed	'	'	7,727	5,580
Total fair value of consideration transferred	'	'	$34,371	€ 24,820

Note_3_Business_Acquisition_De3

Note 3 - Business Acquisition (Details) - Acquisition Pro Forma Information (Merck Sharpe & Dohme's API [Member], USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Merck Sharpe & Dohme's API [Member]	'	'
Note 3 - Business Acquisition (Details) - Acquisition Pro Forma Information [Line Items]	'	'
Net revenues	$156,868	$185,293
Net income (loss)	($9,407)	$10,827
Diluted net income (loss) per share (in Dollars per share)	($0.23)	$0.28

Note_4_Revenue_Recognition_Det

Note 4 - Revenue Recognition (Details) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Revenue Recognition Disclosure [Abstract]	'	'
Product Return Rate, Percentage	1.20%	1.40%
Increase Decrease In Provisions For Product Returns	($1.30)	'
Increase (Decrease) in Sales Returns, Goods	$1	$0.90

Note_4_Revenue_Recognition_Det1

Note 4 - Revenue Recognition (Details) - Analysis of the Chargeback Liability (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Analysis of the Chargeback Liability [Abstract]	'	'
Beginning balance	$18,104	$11,898
Ending balance	12,298	18,104
Provision related to sales made in the current period	118,643	213,075
Credits issued to third parties	($124,449)	($206,869)

Note_4_Revenue_Recognition_Det2

Note 4 - Revenue Recognition (Details) - Analysis of the Product Return Liability (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Analysis of the Product Return Liability [Abstract]	'	'
Beginning balance	$4,592	$2,673
Ending balance	3,289	4,592
Provision for product returns	-261	2,711
Credits issued to third parties	($1,042)	($792)

Note_5_Income_Loss_Per_Share_D

Note 5 - Income (Loss) Per Share (Details) (USD $)	3 Months Ended	9 Months Ended		9 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
				Equity Option [Member]	Employee Stock Option [Member]	Deferred Stock Units (DSUs) [Member]
Note 5 - Income (Loss) Per Share (Details) [Line Items]	'	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,511,431	529,774	'	8,391,236	10,305,452	131,184
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)	$15.14	$15.14	$15.39	$16.54	'	'

Note_5_Income_Loss_Per_Share_D1

Note 5 - Income (Loss) Per Share (Details) - Calculation of Basic and Diluted Net Income (Loss) Per Common Share (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic and dilutive numerator:	'	'	'	'
Net income (loss) (in Dollars)	($5,379)	($159)	($8,178)	$10,033
Denominator:	'	'	'	'
Common shares outstanding	44,642	38,707	41,058	38,699
Contingently issuable shares - vested DSUs	2	2	2	9
Weighted-average common shares outstanding—basic	44,644	38,709	41,060	38,708
Net effect of dilutive securities:	'	'	'	'
Stock options	'	'	'	63
Contingently issuable shares – nonvested DSUs	'	'	'	77
Weighted-average common shares outstanding—diluted	44,644	38,709	41,060	38,848
Net income (loss) per common share—basic (in Dollars per share)	($0.12)	$0	($0.20)	$0.26
Net income (loss) per common share—diluted (in Dollars per share)	($0.12)	$0	($0.20)	$0.26

Note_6_Segment_Reporting_Detai

Note 6 - Segment Reporting (Details)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Number of Reportable Segments	2

Note_6_Segment_Reporting_Detai1

Note 6 - Segment Reporting (Details) - Financial Information by Reporting Segment (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Net Revenue	$59,711	$59,318	$154,584	$174,805
Gross Profit:	'	'	'	'
Gross Profit	11,791	20,280	39,296	67,327
Operating expenses	19,608	20,054	50,255	52,767
Income (loss) from operations	-7,817	226	-10,959	14,560
Non-operating income (expenses)	-167	109	-1,372	-115
Income (loss) before income taxes	-7,984	335	-12,331	14,445
Finished Pharmaceutical Products Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net Revenue	53,729	59,318	148,500	174,805
Gross Profit:	'	'	'	'
Gross Profit	12,122	20,280	39,592	67,327
Active Pharmaceutical Ingredient Segment [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net Revenue	5,982	'	6,084	'
Gross Profit:	'	'	'	'
Gross Profit	($331)	'	($296)	'

Note_6_Segment_Reporting_Detai2

Note 6 - Segment Reporting (Details) - Net Revenues and Carrying Values of Long-Lived Assets of Enterprises by Geographic Regions (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Net Revenue	$59,711	$59,318	$154,584	$174,805	'
Long-Lived Assets	134,112	'	134,112	'	116,619
UNITED STATES	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Net Revenue	53,729	59,318	148,500	174,805	'
Long-Lived Assets	98,744	'	98,744	'	99,398
CHINA	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Long-Lived Assets	21,011	'	21,011	'	17,221
FRANCE	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Net Revenue	5,982	'	6,084	'	'
Long-Lived Assets	$14,357	'	$14,357	'	'

Note_7_Customer_and_Supplier_C2

Note 7 - Customer and Supplier Concentration (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Risks and Uncertainties [Abstract]	'	'	'	'
Number of Major Customers	4	4	4	4

Note_7_Customer_and_Supplier_C3

Note 7 - Customer and Supplier Concentration (Details) - Accounts Receivable and Net Revenues Information for the Company’s Major Customers (Customer Concentration Risk [Member])

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Actavis, Inc. [Member]

Actavis, Inc. [Member]

Actavis, Inc. [Member]

Actavis, Inc. [Member]

Actavis, Inc. [Member]

Actavis, Inc. [Member]

AmerisourceBergen [Member]

AmerisourceBergen [Member]

AmerisourceBergen [Member]

AmerisourceBergen [Member]

AmerisourceBergen [Member]

AmerisourceBergen [Member]

Cardinal Health [Member]

Cardinal Health [Member]

Cardinal Health [Member]

Cardinal Health [Member]

Cardinal Health [Member]

Cardinal Health [Member]

McKesson [Member]

McKesson [Member]

McKesson [Member]

McKesson [Member]

McKesson [Member]

McKesson [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

Revenue, Major Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Customer

31.00%

44.00%

35.00%

32.00%

33.00%

34.00%

10.00%

11.00%

14.00%

15.00%

15.00%

15.00%

10.00%

7.00%

13.00%

13.00%

14.00%

14.00%

16.00%

13.00%

19.00%

29.00%

23.00%

26.00%

Note_8_Fair_Value_Measurements2

Note 8 - Fair Value Measurements (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Assets, Fair Value Adjustment	$0	$0
Liabilities, Fair Value Adjustment	$0	$0

Note_8_Fair_Value_Measurements3

Note 8 - Fair Value Measurements (Details) - Fair Values of the Company’s Financial Assets and Liabilities Measured on a Recurring Basis (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash equivalents:	'	'
Money market accounts	$40,013	$41,183
Restricted short-term investments:	'	'
Certificates of deposit	1,495	1,325
Fair value measurement as of	41,508	42,508
Fair Value, Inputs, Level 1 [Member]	'	'
Cash equivalents:	'	'
Money market accounts	40,013	41,183
Restricted short-term investments:	'	'
Certificates of deposit	1,495	1,325
Fair value measurement as of	$41,508	$42,508

Note_9_Goodwill_and_Intangible2

Note 9 - Goodwill and Intangible Assets (Details) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
Indefinite-Lived Trademarks	$29.20

Note_9_Goodwill_and_Intangible3

Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification (USD $)	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Definite-lived intangible assets, Weighted-Average Life (Years)	'12 years		'11 years
Definite-lived intangible assets, Original Cost	$30,491		$30,496
Definite-lived intangible assets, Accumulated Amortization	21,246		19,838
Definite-lived intangible assets, Net Book Value	9,245		10,658
Indefinite-lived intangible assets, Subtotal, Weighted-Average Life (Years)	'	[1]	'	[1]
Indefinite-lived intangible assets, Subtotal, Original Cost	33,976		29,505
Indefinite-lived intangible assets, Subtotal, Net Book Value	33,976		29,505
Balance, Weighted-Average Life (Years)	'	[1]	'	[1]
Balance, Original Cost	64,467		60,001
Balance, Accumulated Amortization	21,246		19,838
Balance, Net Book Value	43,221		40,163
Goodwill, Weighted-Average Life (Years)	'	[1]	'	[1]
Goodwill, Original Cost	4,649		280
Goodwill, Net Book Value	4,649		280
Trademarks [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Indefinite-lived intangible assets, Weighted-Average Life (Years)	'	[1]	'	[1]
Indefinite-lived intangible assets, Original Cost	29,225		29,225
Indefinite-lived intangible assets, Net Book Value	29,225		29,225
AFP Customers [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Indefinite-lived intangible assets, Weighted-Average Life (Years)	'	[1]	'
Indefinite-lived intangible assets, Original Cost	102		'
Indefinite-lived intangible assets, Net Book Value	102		'
Product Rights [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Definite-lived intangible assets, Weighted-Average Life (Years)	'12 years		'12 years
Definite-lived intangible assets, Original Cost	27,134		27,134
Definite-lived intangible assets, Accumulated Amortization	20,451		19,114
Definite-lived intangible assets, Net Book Value	6,683		8,020
Balance, Accumulated Amortization	20,451		19,114
Patents [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Definite-lived intangible assets, Weighted-Average Life (Years)	'10 years		'10 years
Definite-lived intangible assets, Original Cost	293		298
Definite-lived intangible assets, Accumulated Amortization	71		50
Definite-lived intangible assets, Net Book Value	222		248
Balance, Accumulated Amortization	71		50
Trademarks [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Definite-lived intangible assets, Weighted-Average Life (Years)	'11 years		'11 years
Definite-lived intangible assets, Original Cost	19		19
Definite-lived intangible assets, Accumulated Amortization	13		13
Definite-lived intangible assets, Net Book Value	6		6
Balance, Accumulated Amortization	13		13
Land-Use Rights [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Definite-lived intangible assets, Weighted-Average Life (Years)	'39 years		'39 years
Definite-lived intangible assets, Original Cost	2,540		2,540
Definite-lived intangible assets, Accumulated Amortization	206		156
Definite-lived intangible assets, Net Book Value	2,334		2,384
Balance, Accumulated Amortization	206		156
Other Intangible Assets [Member]	'		'
Note 9 - Goodwill and Intangible Assets (Details) - Weighted-Average Life, Original Cost, Accumulated Amortization, and Net Book Value by Major Intangible Asset Classification [Line Items]	'		'
Definite-lived intangible assets, Weighted-Average Life (Years)	'1 year		'1 year
Definite-lived intangible assets, Original Cost	505		505
Definite-lived intangible assets, Accumulated Amortization	505		505
Balance, Accumulated Amortization	$505		$505
[1]	Intangible assets with indefinite lives have an undeterminable average life.

Note_10_Inventories_Details_An

Note 10 - Inventories (Details) - Analysis of Inventories (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Analysis of Inventories [Abstract]	'	'
Raw materials and supplies	$42,049	$34,470
Work in process	23,558	14,698
Finished goods	23,430	26,501
Total inventory	89,037	75,669
Less reserve for excess and obsolete inventories	-985	-5,753
Total inventory, net	$88,052	$69,916

Note_11_Property_Plant_and_Equ2

Note 11 - Property, Plant, and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 11 - Property, Plant, and Equipment (Details) [Line Items]	'	'
Property, Plant and Equipment, Gross	$233,445	$207,194
Primatene Mist HFA Manufacturing Equipment [Member]	'	'
Note 11 - Property, Plant, and Equipment (Details) [Line Items]	'	'
Property, Plant and Equipment, Gross	$3,200	$3,400

Note_11_Property_Plant_and_Equ3

Note 11 - Property, Plant, and Equipment (Details) - Property, Plant, and Equipment (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Building	$66,764	$58,898
Leasehold improvements	23,942	23,834
Land	7,073	5,805
Machinery and equipment	104,176	93,617
Furniture, fixtures, and automobiles	11,171	9,355
Construction in progress	20,319	15,685
Total property, plant, and equipment	233,445	207,194
Less accumulated depreciation and amortization	-99,333	-90,575
Total property, plant, and equipment, net	$134,112	$116,619

Note_12_Impairment_of_LongLive1

Note 12 - Impairment of Long-Lived Assets (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'	'	'	'
Impairment of Long-Lived Assets Held-for-use	$13	$6	$361	$6

Note_13_Debt_Details

Note 13 - Debt (Details)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Jun. 01, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Apr. 22, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2010

Sep. 30, 2014

Sep. 30, 2014

Sep. 15, 2006

Sep. 30, 2014

Nov. 15, 2010

Sep. 30, 2014

Mar. 15, 2013

Sep. 30, 2014

Apr. 22, 2014

Mar. 05, 2007

Apr. 22, 2014

Apr. 22, 2014

Apr. 22, 2014

Mar. 05, 2012

Jul. 31, 2013

Jul. 05, 2013

Apr. 10, 2012

Apr. 10, 2012

Mar. 05, 2012

15-May-09

Sep. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

USD ($)

USD ($)

Building at Rancho Cucamonga, California [Member]

Building at Rancho Cucamonga, California [Member]

Building at Chino California Member

Scenario, Refinanced [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Line of Credit Facility - Due March 2016 [Member]

Line of Credit Facility - Due January 2019 [Member]

Line of Credit Facility - Due January 2019 [Member]

Revolving Line of Credit - Due May 2016 [Member]

Revolving Line of Credit - Due May 2016 [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Equipment Loan - Due November 2014 [Member]

Equipment Loan - Due November 2014 [Member]

Equipment Loan - Due April 2017 [Member]

Equipment Loan - Due April 2017 [Member]

Mortgage Payable - Due April 2021 [Member]

Mortgage Payable - Due April 2021 [Member]

Mortgage Payable - Due April 2021 [Member]

Acquisition Loan - Due April 2019 [Member]

Acquisition Loan - Due April 2019 [Member]

Acquisition Loan - Due April 2019 [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

East West Bank [Member]

East West Bank [Member]

Minimum [Member]

USD ($)

EUR (€)

USD ($)

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due September 2016 [Member]

Mortgage Payable - Due January 2016 [Member]

Mortgage Payable - Due April 2021 [Member]

Minimum [Member]

East West Bank [Member]

East West Bank [Member]

London Interbank Offered Rate (LIBOR) [Member]

East West Bank [Member]

East West Bank [Member]

Minimum [Member]

East West Bank [Member]

Minimum [Member]

East West Bank [Member]

Cathay Bank [Member]

Cathay Bank [Member]

Cathay Bank [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

Merck Sharpe & Dohme's API [Member]

East West Bank [Member]

Prime Rate [Member]

East West Bank [Member]

Minimum [Member]

Cathay Bank [Member]

USD ($)

USD ($)

East West Bank [Member]

East West Bank [Member]

East West Bank [Member]

Cathay Bank [Member]

East West Bank [Member]

USD ($)

USD ($)

East West Bank [Member]

USD ($)

USD ($)

East West Bank [Member]

USD ($)

East West Bank [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Minimum [Member]

Cathay Bank [Member]

Cathay Bank [Member]

USD ($)

East West Bank [Member]

USD ($)

Cathay Bank [Member]

USD ($)

USD ($)

Cathay Bank [Member]

USD ($)

Note 13 - Debt (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

$4,600,000

'

'

$4,500,000

'

'

$2,800,000

'

$3,200,000

'

$4,900,000

'

'

$5,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

'

'

'

'

'

'

'

'

3,800,000

'

'

2,200,000

'

'

'

'

'

'

3,900,000

'

'

'

12,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Number of Buildings Securing Loan

'

'

'

1

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

5.00%

'

3.50%

'

'

5.42%

'

4.00%

'

'

'

'

'

4.00%

'

'

'

4.00%

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

'

'

'

'

2.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

8,000,000

'

20,000,000

8,000,000

8,000,000

'

'

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Fair Value Disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,600,000

'

'

'

'

21,900,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Term

'120 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Loan Collateral Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Consideration Transferred, Liabilities Incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,000,000

11,600,000

'

'

Business Acquisition Purchase Price Obligation Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'4 years

'

'

Business Acquisition Interest On Purchase Price Obligation State Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

Long-term Debt and Capital Lease Obligations

'

41,271,000

10,069,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,700,000

'

Capital Leased Assets, Gross

'

1,600,000

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation

'

$400,000

$200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_13_Debt_Details_Debt_Cons

Note 13 - Debt (Details) - Debt Consists of the Following (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Payment obligation to Merck	$14,740	'
Equipment under Capital Leases	1,113	1,258
Total debt and capital leases	51,349	32,173
Less current portion of long-term debt and capital leases	10,078	22,104
Long-term debt, net of current portion and capital leases	41,271	10,069
Mortgage Payable - Due January 2016 [Member] | Secured Debt [Member] | East West Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Long Term Debt	3,927	4,041
Mortgage Payable - Due September 2016 [Member] | Secured Debt [Member] | East West Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Long Term Debt	2,308	2,364
Equipment Loan - Due November 2014 [Member] | Secured Debt [Member] | East West Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Long Term Debt	145	783
Equipment Loan - Due April 2017 [Member] | Secured Debt [Member] | East West Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Long Term Debt	3,222	4,103
Mortgage Payable - Due April 2021 [Member] | Secured Debt [Member] | Cathay Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Long Term Debt	4,571	4,624
Revolving Line of Credit - Due May 2016 [Member] | Revolving Credit Facility [Member] | Cathay Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Line of Credit	'	15,000
Acquisition Loan - Due April 2019 [Member] | Cathay Bank [Member]	'	'
Note 13 - Debt (Details) - Debt Consists of the Following [Line Items]	'	'
Long Term Debt	$21,323	'

Note_14_Income_Taxes_Details

Note 14 - Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Effective Income Tax Rate Reconciliation, Percent	-32.60%	147.50%	-33.70%	30.50%	'
Deferred Tax Liabilities, Undistributed Foreign Earnings (in Dollars)	($9.80)	'	($9.80)	'	($5)
Scenario, Expected at December 31, 2014 [Member]	'	'	'	'	'
Note 14 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Effective Income Tax Rate Reconciliation, Percent	'	'	33.80%	'	'

Note_14_Income_Taxes_Details_I

Note 14 - Income Taxes (Details) - Income Tax Provision (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Provision [Abstract]	'	'	'	'
Income (loss) before taxes	($7,984)	$335	($12,331)	$14,445
Income tax provision (benefit)	-2,605	494	-4,153	4,412
Net income (loss)	($5,379)	($159)	($8,178)	$10,033
Income tax provision (benefit) as a percentage of income before income taxes	-32.60%	147.50%	-33.70%	30.50%

Note_15_Stockholders_Equity_De

Note 15 - Stockholders' Equity (Details) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Jun. 25, 2014

Jun. 25, 2014

Sep. 30, 2014

Jun. 25, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

IPO [Member]

IPO [Member]

IPO [Member]

IPO [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Deferred Stock Units (DSUs) [Member]

Deferred Stock Units (DSUs) [Member]

Deferred Stock Units (DSUs) [Member]

Deferred Stock Units (DSUs) [Member]

Deferred Stock Units (DSUs) [Member]

Underwriter [Member]

The 2005 Plan [Member]

Directors and Employees [Member]

Note 15 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

1,200,000

5,840,000

'

'

'

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

'

$7

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance Initial Public Offering

$40,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Stock Issuance Costs

'

'

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance Initial Public Offering, Net of Issuance Costs

34,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

2,000,000

2,200,000

5,100,000

4,500,000

'

500,000

200,000

1,200,000

400,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

'

'

'

'

'

13,800,000

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'2 years 6 months

'

'

'

'

'

'

'

'3 years 146 days

'

Share-based Compensation Arrangement by Share-based Payment Award, Deferred Stock Units, Number of Shares of Common Stock Per Award (in Shares)

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options

'

'

'

'

'

'

'

'

'

'

'

$5,800,000

'

$5,800,000

'

Note_15_Stockholders_Equity_De1

Note 15 - Stockholders' Equity (Details) - Summary of Stockholders' Equity (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 15 - Stockholders' Equity (Details) - Summary of Stockholders' Equity [Line Items]	'	'	'	'
Stockholders’ equity	'	'	$251,545	'
Net loss	-5,379	-159	-8,178	10,033
Accumulated other comprehensive loss	'	'	-1,803	'
Common stock issued through initial public offering	'	'	38,018	'
Common stock issued to employees, net of shares withheld	'	'	-485	'
Cost related to public offering	-3,358	'	-3,358	'
Exercise of stock options	'	'	701	'
Stockholders’ equity	283,120	'	283,120	'
Nonemployee [Member]	'	'	'	'
Note 15 - Stockholders' Equity (Details) - Summary of Stockholders' Equity [Line Items]	'	'	'	'
Nonemployee share-based compensation expense	'	'	728	'
Employee [Member]	'	'	'	'
Note 15 - Stockholders' Equity (Details) - Summary of Stockholders' Equity [Line Items]	'	'	'	'
Employee share-based compensation expense	'	'	$5,952	'

Note_15_Stockholders_Equity_De2

Note 15 - Stockholders' Equity (Details) - Weighted-Averages for Key Assumptions Used in Determining the Fair Value of Options Granted	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Weighted-Averages for Key Assumptions Used in Determining the Fair Value of Options Granted [Abstract]	'	'	'
Average volatility	28.30%	29.90%	28.50%
Risk-free interest rate	1.20%	1.70%	1.20%
Weighted-average expected life in years	'4 years 146 days	'5 years	'4 years 146 days
Dividend yield rate	0.00%	0.00%	0.00%

Note_15_Stockholders_Equity_De3

Note 15 - Stockholders' Equity (Details) - Summary of Option Activity (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014
Summary of Option Activity [Abstract]	'
Outstanding as of December 31, 2013	10,771,755
Outstanding as of December 31, 2013	$15.39
Outstanding as of September 30, 2014	11,511,431
Outstanding as of September 30, 2014	$15.14
Outstanding as of September 30, 2014	'4 years 317 days
Outstanding as of September 30, 2014	$1,975	[1]
Exercisable as of September 30, 2014	5,732,361
Exercisable as of September 30, 2014	$17.27
Exercisable as of September 30, 2014	'3 years 219 days
Exercisable as of September 30, 2014	$806	[1]
Options granted	1,661,862
Options granted	$15.04
Options exercised	-65,000
Options exercised	$10.79
Options cancelled	-60,198
Options cancelled	$12.11
Options expired	-796,988
Options expired	$18.86
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company's common stock for those awards that have an exercise price below the estimated fair value at September 30, 2014.

Note_15_Stockholders_Equity_De4

Note 15 - Stockholders' Equity (Details) - Option Grants and Exercises (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Option Grants and Exercises [Abstract]	'	'	'	'
Weighted-average grant date fair value (in Dollars per share)	'	$2.50	$4.02	$2.54
Intrinsic value of options exercised	$283	$4	$144	($1)
Cash received	130	38	701	51
Total fair value of the options vested during the year	$3,510	$3,203	$4,324	$4,056

Note_15_Stockholders_Equity_De5

Note 15 - Stockholders' Equity (Details) - Summary of Nonvested Options (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Summary of Nonvested Options [Abstract]	'	'	'
Nonvested as of December 31, 2013	'	5,617,554	'
Nonvested as of December 31, 2013	'	$3.12	'
Nonvested as of September 30, 2014	'	5,779,070	'
Nonvested as of September 30, 2014	'	$3.39	'
Options granted	'	1,661,862	'
Options granted	$2.50	$4.02	$2.54
Options vested	'	-1,440,148	'
Options vested	'	$3	'
Options forfeited	'	-60,198	'
Options forfeited	'	$4.35	'

Note_15_Stockholders_Equity_De6

Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014		Sep. 30, 2013
Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries [Line Items]	'	'	'		'
Common stock delivered	-2,000	-2,000	-2,000		-9,000
Deferred Stock Units (DSUs) [Member]	'	'	'		'
Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries [Line Items]	'	'	'		'
DSUs outstanding at December 31, 2013	'	'	98,495		'
DSUs outstanding at September 30, 2014	529,774	'	529,774		'
DSUs granted	'	'	449,544		'
DSUs forfeited	'	'	-994		'
Common stock delivered	'	'	-9,497		'
DSUs surrendered for taxes	'	'	-7,774		'
Deferred Stock Units Issued as Compensation [Member]	'	'	'		'
Note 15 - Stockholders' Equity (Details) - Information Relating to DSU Grants and Deliveries [Line Items]	'	'	'		'
DSUs granted (in Dollars)	'	'	6,389	[1]	'
[1]	The total FMV is derived from the number of DSUs granted times the current stock price on the date of grant.

Note_16_Commitments_and_Contin1

Note 16 - Commitments and Contingencies (Details)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

80 Months Ended

13 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Nov. 30, 2012

Jan. 31, 2010

Nov. 30, 2012

31-May-05

Jan. 31, 2012

Sep. 30, 2014

Dec. 31, 2011

Dec. 31, 2013

Jan. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Jul. 31, 2014

Jul. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 31, 2014

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

ANP [Member]

Agreements With a Chinese Governmental Entity [Member]

Agreements With a Chinese Governmental Entity [Member]

Agreements With a Chinese Governmental Entity [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Exclusive Marketing Rights for Enoxaparin [Member]

Land-Use Rights [Member]

Land-Use Rights [Member]

Insuling Supply Agreement With MannKind [Member]

Insuling Supply Agreement With MannKind [Member]

Research and Development Arrangement [Member]

Minimum [Member]

Maximum [Member]

Commitments to Purchase Equipment and Raw Materials [Member]

MannKind Corporation [Member]

Agreements With a Chinese Governmental Entity [Member]

Land-Use Rights [Member]

Land-Use Rights [Member]

USD ($)

Andrx Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

Watson Pharmaceuticals, Inc. [Member]

Actavis, Inc. [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Note 16 - Commitments and Contingencies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Customers

'

'

'

'

'

'

'

'

'

$4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Revenue, Additions

'

'

'

'

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognition of Deferred Revenue

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Deferred Revenue, Period for Recognition

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Distribution Agreement With Corporate Partner, Renewal Option Period

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'3 years

'

'

'

'

'

'

'

'

'

Deferred Revenue

'

'

'

'

'

'

'

'

'

'

'

2,800,000

'

3,300,000

'

'

'

14,000,000

11,000,000

'

'

'

'

'

Supply Commitment, Remaining Minimum Amount Committed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152,300,000

120,100,000

'

'

'

'

'

Long-term Supply Commitment, Optional Renewal Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

Lessee Leasing Arrangements, Operating Leases, Renewal Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'6 years

'

'

Operating Leases, Rent Expense

800,000

800,000

2,300,000

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Purchase Commitment, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,700,000

'

Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures

'

'

'

'

'

41,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registered Capital Commitment to Subsidiary

'

'

'

'

'

61,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual Obligation

14,740,000

'

14,740,000

'

'

20,000,000

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

30,491,000

'

30,491,000

'

30,496,000

'

1,300,000

1,200,000

'

'

'

'

'

'

'

2,540,000

2,540,000

'

'

'

'

'

'

'

Purchase Commitments Amount Fulfilled

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,200,000

'

'

'

'

Note_17_Litigation_Details

Note 17 - Litigation (Details) (Enoxaparin Patent Litigation [Member], Momenta and Sandoz [Member], USD $)	0 Months Ended	9 Months Ended		0 Months Ended
	Oct. 31, 2011	Sep. 30, 2014	Sep. 21, 2011	Jan. 24, 2014
	Pending Litigation [Member]	Pending Litigation [Member]	Pending Litigation [Member]	Judicial Ruling [Member]
Note 17 - Litigation (Details) [Line Items]	'	'	'	'
Number of Alleged Patent Infringements	'	'	2	'
Litigation, Plaintiff Preliminary Injunction Bond, Amount	$100,100,000	'	'	'
Litigation Settlement, Expense	'	'	'	40,000
Loss Contingency, Damages Sought, Value	'	$100,100,000	'	'

Note_18_Subsequent_Events_Deta

Note 18 - Subsequent Events (Details) (Subsequent Event [Member], USD $)	Nov. 06, 2014
In Millions, unless otherwise specified
Subsequent Event [Member]	'
Note 18 - Subsequent Events (Details) [Line Items]	'
Stock Repurchase Program, Authorized Amount	$10